WO2024085659A1 - Composition for preventing or treating oral disease, containing steamed ginseng berry extract as active ingredient - Google Patents
Composition for preventing or treating oral disease, containing steamed ginseng berry extract as active ingredient Download PDFInfo
- Publication number
- WO2024085659A1 WO2024085659A1 PCT/KR2023/016183 KR2023016183W WO2024085659A1 WO 2024085659 A1 WO2024085659 A1 WO 2024085659A1 KR 2023016183 W KR2023016183 W KR 2023016183W WO 2024085659 A1 WO2024085659 A1 WO 2024085659A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- ginseng fruit
- preventing
- steamed
- oral
- Prior art date
Links
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 144
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 143
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 141
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 208000025157 Oral disease Diseases 0.000 title claims abstract description 23
- 208000030194 mouth disease Diseases 0.000 title claims abstract description 23
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- 241000208340 Araliaceae Species 0.000 title claims abstract 9
- 235000021028 berry Nutrition 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 claims abstract description 44
- 210000002379 periodontal ligament Anatomy 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 230000014509 gene expression Effects 0.000 claims abstract description 19
- 230000004069 differentiation Effects 0.000 claims abstract description 11
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 9
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 6
- 210000000963 osteoblast Anatomy 0.000 claims abstract description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 137
- 201000001245 periodontitis Diseases 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 22
- 230000000844 anti-bacterial effect Effects 0.000 claims description 12
- 102000016938 Catalase Human genes 0.000 claims description 10
- 108010053835 Catalase Proteins 0.000 claims description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 10
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 10
- ZVTVWDXRNMHGNY-JOGTXEPTSA-N Ginsenoside Rg6 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](C(=C)CC/C=C(\C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZVTVWDXRNMHGNY-JOGTXEPTSA-N 0.000 claims description 8
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 8
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 7
- 208000007565 gingivitis Diseases 0.000 claims description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
- 102000004067 Osteocalcin Human genes 0.000 claims description 6
- 108090000573 Osteocalcin Proteins 0.000 claims description 6
- OZTXYFOXQFKYRP-RISAHGKBSA-N Ginsenoside Rh4 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1 OZTXYFOXQFKYRP-RISAHGKBSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- QOMBXPYXWGTFNR-KRPFXEAISA-N (20E)-Ginsenoside F4 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 QOMBXPYXWGTFNR-KRPFXEAISA-N 0.000 claims description 4
- 208000002925 dental caries Diseases 0.000 claims description 4
- 239000002324 mouth wash Substances 0.000 claims description 4
- 229940051866 mouthwash Drugs 0.000 claims description 4
- OZTXYFOXQFKYRP-TXRYYSRHSA-N Ginsenoside Rh4 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZTXYFOXQFKYRP-TXRYYSRHSA-N 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 229940041672 oral gel Drugs 0.000 claims description 2
- 229940042125 oral ointment Drugs 0.000 claims description 2
- 239000000668 oral spray Substances 0.000 claims description 2
- 229940041678 oral spray Drugs 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 239000002966 varnish Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 17
- 102000004127 Cytokines Human genes 0.000 abstract description 12
- 108090000695 Cytokines Proteins 0.000 abstract description 12
- 240000004371 Panax ginseng Species 0.000 description 134
- 239000012141 concentrate Substances 0.000 description 102
- 235000008504 concentrate Nutrition 0.000 description 101
- 239000000843 powder Substances 0.000 description 57
- 241000894006 Bacteria Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 208000028169 periodontal disease Diseases 0.000 description 17
- 229930182494 ginsenoside Natural products 0.000 description 16
- 229940089161 ginsenoside Drugs 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000004072 osteoblast differentiation Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 238000010025 steaming Methods 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000003239 periodontal effect Effects 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- -1 olive oil Chemical compound 0.000 description 4
- 230000001582 osteoblastic effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000005373 Panax quinquefolius Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 241000180649 Panax notoginseng Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- 241001527087 Panax vietnamensis Species 0.000 description 2
- 235000017726 Panax vietnamensis Nutrition 0.000 description 2
- 206010072574 Periodontal inflammation Diseases 0.000 description 2
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000589892 Treponema denticola Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 235000003174 Panax japonicus Nutrition 0.000 description 1
- 244000133018 Panax trifolius Species 0.000 description 1
- 235000003177 Panax trifolius Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001135235 Tannerella forsythia Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 210000001648 gingival epithelial cell Anatomy 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Definitions
- the present invention relates to a composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient.
- Oral diseases are diseases that occur within the oral cavity, and can affect anyone, including periodontal disease (periodontal disease) and dental caries (cavities), and can cause pain, masticatory dysfunction, destruction of periodontal tissue, bad breath, and coldness. It is known to be the main factor that causes various symptoms and causes tooth loss.
- Periodontal disease is a chronic disease with a very high prevalence, affecting more than 7 out of 10 adults. Periodontal disease is largely divided into gingivitis and periodontitis. When the inflammation is limited to the gums, or soft tissue, it is called gingivitis, and when this inflammation progresses to the gums and gum bones, it is called periodontitis.
- Periodontitis which is caused by complex causes caused by periodontitis bacteria such as gingivalis, causes inflammation of the tooth-supporting structure and simultaneously causes destruction of the periodontal ligament and loss of alveolar bone, so it has complex antibacterial and anti-inflammatory properties, and promotion of osteoblast differentiation.
- a treatment method is needed.
- the most effective treatment for periodontitis is a combination of drug treatment and surgery, but this treatment method has a poor treatment prognosis and can cause pain and side effects in patients.
- drugs used to treat oral diseases such as antibacterial and anti-inflammatory drugs, are not treatments for fundamental periodontal disease and are accompanied by side effects due to long-term use. Accordingly, there is a need to secure natural materials and discover new herbal medicine/natural materials for the prevention and treatment of periodontitis.
- ginseng fruit is a rare fruit that grows from May to July in 4-year-old ginseng. Previously, it was simply recognized as a ginseng seed, but through clinical trials and research results in the medical community in the United States, Japan, and Korea, it was revealed that it contains a large amount of ginsenoside, a saponin of ginseng. However, due to the nature of ginseng fruits, which wither within a day after harvesting, they require intensive harvesting in a short period of time, making cultivation and management difficult.
- Korean Patent No. 10-1394832 describes a composition for suppressing oral bacteria containing ginseng fruit extract as an active ingredient
- Korean Patent Publication No. 10-2016-00065472 describes the pulp and skin of ginseng fruit.
- a seed processing method of ginseng fruit is disclosed in which the seed is removed and only the seeds are roasted to produce a fine powder.
- research is needed to increase the utilization rate of ginseng fruits and enhance their medicinal properties through appropriate processing of ginseng fruits to discover new uses.
- the purpose of the present invention is to provide a composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient.
- the present invention provides a composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient.
- the steamed ginseng fruit extract can be used in a concentrated form, and the steamed ginseng fruit concentrate can be used in the form of a powder obtained by freeze-drying the steamed ginseng fruit concentrate or the steamed ginseng fruit concentrate.
- the steamed ginseng fruit extract is an extraction concentrate of ginseng fruit water, lower alcohol (methanol, ethanol, propanol, butanol), lower alcohol aqueous solution, or organic solvent (chloroform, ethyl acetate, dichloromethane, dimethyl sulfoxide, hexane, etc.) It contains a steamed ginseng fruit concentrate steamed at 100-130°C and 0.11-15 MPa for 4-12 hours, and the extraction solvent for the ginseng fruit is preferably water or lower alcohol (methanol, ethanol, propanol, butanol). , an aqueous solution of lower alcohol, more preferably 30 to 99% ethanol.
- the steamed ginseng fruit extract may be obtained by steaming 50% alcohol extract of ginseng fruit at a temperature of 100 to 130°C and a pressure of 0.11 to 15 MPa for 4 to 12 hours.
- the steamed ginseng fruit extract may be a steamed ginseng fruit concentrate steamed by microwave treatment at high temperature and high pressure.
- the steamed ginseng fruit concentrate steamed by microwave treatment at high temperature and high pressure is extracted from ginseng fruit water, lower alcohol (methanol, ethanol, propanol, butanol), or lower alcohol aqueous solution at 300 to 400 W, 2.5 to 3.5 MPa.
- the steamed ginseng fruit concentrate steamed at high temperature and pressure or by microwave treatment at high temperature and pressure contains the active ingredients 0.5 to 2% by weight of ginsenoside Rg6, 0.5 to 2% by weight of ginsenoside Rg4, and ginsenoside. It may contain 0.5 to 5% by weight of side Rh4.
- the oral disease may be dental caries, periodontitis, or gingivitis.
- “dental cavities” refers to an infectious disease caused by bacteria living on the surface of teeth. Also called cavities, it is specifically a milky-white, translucent, hard substance that covers the surface of the head of the tooth and protects the dentin of the tooth. It occurs when tooth enamel or enamel is damaged by acids produced during the decomposition of sugar, starch, etc. by oral pathogens that live in the mouth.
- gingiva is a disease in which inflammation occurs in the gingiva, periodontal ligament, and bone tissue that support the teeth.
- gingivitis is a form of periodontal disease limited to the gums, i.e., soft tissue.
- Treponema denticola and Fusobacterium nucleatum may be one or more species selected from the group consisting of, and more specifically, Porphyromonas gingivalis.
- the Porphyromonas gingivalis is a type of Bacteroide soft bacteria, a Gram-negative bacterium, an anaerobic bacterium, and is found in the oral cavity where periodontal disease occurs, and is also found in the upper gastrointestinal tract, respiratory tract, and colon.
- collagen is decomposed by the collagenase enzyme of the bacteria, and the bacteria can invade gingival fibroblasts and survive even under high concentrations of antibiotics. Additionally, the bacteria can invade gingival epithelial cells and survive for a long time.
- composition for preventing or treating oral diseases containing the steamed ginseng fruit extract of the present invention as an active ingredient has an antibacterial effect against the causative bacteria that cause periodontal disease, and in particular has an antibacterial effect against the Porphyromonas gingivalis strain. It is characterized by having
- the ginseng fruit of the present invention is Korean ginseng ( Panax ginseng ), American ginseng ( Panax quinquefolius ), Panax notoginseng ( Panax notoginseng ), Panax japonicus , trifoliate ginseng (American ginseng; Panax trifolius ), and Himalayan ginseng ( Panax ). pseudoginseng ) or Vietnamese ginseng ( Panax vietnamensis ) fruits can be used, but are not limited to these.
- the composition for preventing or treating oral diseases containing the steamed ginseng fruit extract of the present invention as an active ingredient can inhibit the expression of inflammatory cytokines such as IL-6, IL-1 ⁇ or TNF- ⁇ in periodontal ligament cells.
- the composition can induce differentiation of osteoblasts from periodontal ligament cells, and the induction of differentiation of osteoblasts increases the expression of alkaline phosphatase (ALP) or osteocalcin (OCN) or matrix metalloproteinase. It may be inhibiting the expression of matrix metalloproteinase (MMP).
- ALP alkaline phosphatase
- OCN osteocalcin
- MMP matrix metalloproteinase
- composition for preventing or treating oral diseases containing the steamed ginseng fruit extract of the present invention as an active ingredient can prevent or treat oral diseases through antioxidant activity in periodontal ligament cells.
- CAT catalase
- GPx glutathione peroxidase
- ROS reactive oxygen species
- composition according to the present invention can be provided as a pharmaceutical composition and can be formulated in a suitable form with a commonly used pharmaceutically acceptable carrier.
- “Pharmaceutically acceptable” refers to a composition that is physiologically acceptable and does not typically cause allergic or similar reactions such as gastrointestinal upset, dizziness, etc. when administered to humans.
- the composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods.
- the composition of the present invention is in the form of one or more selected from the group consisting of toothpaste, mouthwash, mouthwash, gum, candy, oral spray, oral gel, oral ointment, oral varnish, gum massage cream, and oral patch. It can be formulated as:
- Carriers, excipients, and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, and methyl. It may include, but is not limited to, cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl paraoxybenzoate, propyl paraoxybenzoate, talc, magnesium stearate, and mineral oil.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the ginsenoside of the present invention with at least one excipient, such as starch, microcrystalline cellulose, sucrose or It is prepared by mixing lactose, low-substituted hydroxypropyl cellulose, and hypromellose. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, and syrups.
- Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
- Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.
- injectable ester such as ethyl oleate.
- the ginsenoside or a pharmaceutically acceptable salt thereof is sterilized or added with preservatives, stabilizers, wetting agents or emulsification accelerators, auxiliaries such as salts or buffers for osmotic pressure adjustment, and other therapeutic agents. It can be prepared as a solution or suspension by mixing it in water with useful substances, and it can be prepared in ampoule or vial unit dosage form.
- the pharmaceutical composition can be administered to mammals such as rats, livestock, and humans through various routes. All modes of administration are contemplated, for example, oral, rectal or by intravenous, intramuscular, subcutaneous, intrathecal or intracerebrovascular injection.
- the dosage is determined by the age, gender, and weight of the subject to be treated, the specific disease or pathological state to be treated, the severity of the disease or pathological state, administration time, route of administration, absorption, distribution and excretion rate of the drug, types of other drugs used, and the prescriber's It will vary depending on judgment, etc. Dosage determinations based on these factors are within the level of one skilled in the art, and dosages generally range from 0.01 mg/kg/day to approximately 5000 mg/kg/day. A more preferred dosage is 1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
- the present invention provides a health functional food for preventing or improving oral diseases containing a steamed ginseng fruit concentrate.
- the health functional food refers to food manufactured or processed using raw materials or ingredients with useful functionality, and includes, for example, health supplements, functional foods, nutrients, supplements, etc.
- the steamed ginseng fruit concentrate is preferably 0.001% by weight to 50% by weight, more preferably 0.001% by weight to 40% by weight, and most preferably 0.001% by weight to 30% by weight, based on the total weight of the entire health functional food. It can be added. The above addition amount does not limit the scope of the present invention in any way.
- the health functional food of the present invention includes forms such as tablets, capsules, pills, and liquids.
- Foods to which the ginsenoside of the present invention can be added include, for example, various foods, beverages, gum, tea, and vitamins. There are combination drugs, etc.
- the present invention relates to a composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient, and specifically, inhibits the expression of inflammatory cytokines such as IL-6, IL-1 ⁇ or TNF- ⁇ in periodontal ligament cells. It induces the differentiation of osteoblasts and exhibits antioxidant activity, making it useful for the prevention and treatment of oral diseases.
- inflammatory cytokines such as IL-6, IL-1 ⁇ or TNF- ⁇ in periodontal ligament cells. It induces the differentiation of osteoblasts and exhibits antioxidant activity, making it useful for the prevention and treatment of oral diseases.
- Figure 1 is a graph showing the effect of steamed ginseng fruit concentrate and steamed ginseng fruit concentrate powder according to the present invention on the expression of inflammatory cytokines in human periodontal ligament cells treated with PS-LPS.
- Figure 2 is a graph showing the effect of the steamed ginseng fruit concentrate according to the present invention on osteoblast differentiation in human periodontal ligament cells treated with PS-LPS.
- Figure 3 is a graph showing the effect of the steamed ginseng fruit concentrate powder according to the present invention on osteoblast differentiation in human periodontal ligament cells treated with PS-LPS.
- Figure 4 is a graph showing the effect on the antioxidant activity of the steamed ginseng fruit concentrate according to the present invention in human periodontal ligament cells treated with PS-LPS.
- Figure 5 is a graph showing the effect on the antioxidant activity of the steamed ginseng fruit concentrate powder according to the present invention in human periodontal ligament cells treated with PS-LPS.
- Figure 6 is a result showing the MIC test against Porphyromonas gingivalis of the steamed ginseng fruit concentrate according to the present invention.
- Figure 7 shows the results of an MIC test against Porphyromonas gingivalis of the steamed ginseng fruit concentrate powder according to the present invention.
- Figure 8 shows the results of the MBC test for Porphyromonas gingivalis of the steamed ginseng fruit concentrate according to the present invention.
- Figure 9 is a result showing the MBC test for Porphyromonas gingivalis of the steamed ginseng fruit concentrate powder according to the present invention.
- ginseng fruit concentrate 600kg of 50% alcohol was added to 50kg of ginseng fruit and extracted twice for 6 hours at 85°C. Then, the extract was filtered and concentrated to 70 brix to obtain ginseng fruit concentrate.
- Table 1 summarizes the types and contents of ginsenoside components in ginseng fruit concentrate concentrated to 70 brix without undergoing a steaming process.
- Ginsenoside Comparative Example 1 Ginseng fruit concentrate before steaming Ginsenoside content (mg/g) Example 1. Ginsenoside content in ginseng fruit concentrate steamed at high temperature and pressure (mg/g) Example 2. Ginseng fruit concentrate processed by microwave steaming at high temperature and pressure Ginsenoside content (mg/g) Re+Rg1 64.93 5.61 0 Rb1 21.97 4.88 0 Rc 17.64 5.71 0 Rb2 15.68 6.71 0 Rd 16.23 13.21 0 Rg2-S 2.87 14.19 7.37 Rh1-S 0 1.37 3.04 Rg2-R 0 5.01 3.98 Rh1-R 0 1.03 2.35 Rg6 0 10.38 10.15 Rg4 0 11.31 10.99 Rh4 0 11.98 30.08 Rg3-S 0 7.78 9.18 Rg3-R 0 7.18 9.33 Rk1 0 6.03 14.42 Rg5 0 8.66 19.44 total amount 139.32 121.04 120.33
- Table 1 above summarizes the types of ginsenoside components and their contents according to the treatment after concentrating ginseng fruit. While the ginseng fruit concentrate before steaming (Comparative Example 1) contains a lot of ginsenoside Re+Rg1, it is concentrated at high temperature and pressure. In the steamed ginseng fruit concentrate (Example 1), the ginsenoside components (Re+Rg1, Rb1, Rc, Rb2, Rd) present before steaming were reduced, and low molecular weight ginsenosides Rg6, Rg4, Rh4, Rg2, Rh1, Rg3, Rk1, Rg5, etc. were produced, and in particular, it was confirmed that ginsenoside Rg6, Rg4, and Rh4 components were significantly increased.
- Example 2 In addition, in the ginseng fruit concentrate (Example 2) that was microwave-steamed at high temperature and pressure, the ginsenoside components that existed before steaming were completely destroyed, and the steamed ginseng fruit concentrate with significantly enhanced ginsenoside Rg6, Rg4, and Rh4 components was obtained. I was able to make it.
- the ginseng fruit concentrate steamed at high temperature and high pressure according to Example 2 was used, and the steamed ginseng fruit concentrate steamed at high temperature and high pressure was frozen to facilitate storage and distribution. This was conducted using dried steamed ginseng fruit concentrate powder.
- Representative periodontal pathogens among oral bacteria include Porphyromonas gingivalis, Treponema denticola, Prevotella intermedia , and Aggregatibacter actinomycetemcomitans .
- the lipopolysaccharides (LPS) endotoxins or metabolites formed by these microorganisms increase the secretion of proinflammatory cytokines from tissues and immune cells.
- These pro-inflammatory cytokines damage periodontal tissue and destroy connective tissue by inducing enzyme activity such as matrix metalloproteinase (MMP). Therefore, inhibition of these pro-inflammatory cytokines in periodontitis is an important treatment strategy for suppressing periodontitis. Accordingly, the effect of steamed ginseng fruit concentrate on regulating representative inflammatory cytokines of periodontal inflammation in human periodontal ligament cells stimulated with Porphyromonas gingivalis -LPS (PG-LPS) was evaluated.
- PG-LPS Porphyromonas gingivalis
- Human periodontal ligament cells were donated and used by Kyungpook National University College of Dentistry.
- Human preiodontal ligament (HPDL) cells were cultured in a 96-well plate at a concentration of 5 ⁇ 10 3 cell/mL at a temperature of 37°C and 5% CO 2 . Cultured for 24 hours under culture conditions. Afterwards, the steamed ginseng fruit concentrate or steamed ginseng fruit concentrate powder was treated at concentrations of 0, 50, 100, 150, and 200 ⁇ g/mL and incubated at a temperature of 37°C and 5% CO 2. Cultured for 6 hours under culture conditions.
- both steamed ginseng fruit concentrate and steamed ginseng fruit concentrate powder suppressed the expression of IL-6, IL-1 ⁇ , and TNF ⁇ in a concentration-dependent manner.
- steamed ginseng fruit concentrate powder significantly down-regulated the expression of IL-6 at a lower concentration than steamed ginseng fruit concentrate.
- steamed ginseng fruit concentrate or steamed ginseng fruit concentrate powder can effectively downregulate inflammatory mediators and cytokines increased by PG-LPS in human periodontal ligament cells, thereby exhibiting an inhibitory effect on periodontal inflammation.
- HPDL cells Human periodontal ligament (HPDL) cells were grown in a 24-well plate at a concentration of 5 ⁇ 10 2 cell/mL at a temperature of 37°C and 5% CO 2 Cultured for 24 hours under culture conditions. After removing the culture medium, the culture medium was replaced with ⁇ -MEM containing 10% fetal bovine serum, 100U/ml penicilline, 100 ⁇ g/mL streptomycin, 50 ⁇ g/mL ascorbic acid, and 10 mM ⁇ -glycerophosphate to promote osteoblast differentiation. induced.
- both steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) increased the osteoblast differentiation ability of human periodontal ligament cells, whose osteoblast differentiation was suppressed by PG-LPS. It effectively induced mineralization of human periodontal ligament cells.
- HPDL cells Human preiodontal ligament (HPDL) cells were cultured in a 6-well plate at a concentration of 5 ⁇ 10 5 cells/mL at a temperature of 37°C and 5% CO 2 . Cultured for 24 hours under culture conditions. Afterwards, steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) was treated for 6 hours at concentrations of 0, 50, 100, 150, and 200 ⁇ g/mL, followed by PG-LPS (1 ⁇ g/mL). was stimulated for 12 hours.
- EX steamed ginseng fruit concentrate
- EX powder steamed ginseng fruit concentrate powder
- MMP9 Microx metalloproteinase 9
- HPDL cells Human preiodontal ligament (HPDL) cells were cultured in a 6-well plate at a concentration of 5 ⁇ 10 3 cell/mL at a temperature of 37°C and 5% CO 2 . Cultured for 24 hours under culture conditions. Afterwards, 0, 50, 100, 150, and 200 ⁇ g/mL of steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) and PG-LPS (1 ⁇ g/mL) were treated at a temperature of 37°C, 5% CO2 Cultured for 2 hours under culture conditions.
- EX steamed ginseng fruit concentrate
- EX powder steamed ginseng fruit concentrate powder
- PG-LPS PG-LPS (1 ⁇ g/mL
- both steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) reduced the increased production of reactive oxygen species (ROS) due to PG-LPS in a concentration-dependent manner.
- ROS reactive oxygen species
- These active oxygen species cause periodontitis by causing non-selective and irreversible destruction of cellular components such as phospholipids, proteins, sugars, and DNA. Therefore, it can be seen that steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) improves periodontitis by measuring the effect of suppressing oxidative stress through antioxidant action.
- Superoxide dismutase SOD
- catalase CAT
- glutathione peroxidase GPx
- SOD superoxide dismutase
- CAT catalase
- GPx glutathione peroxidase
- HPDL cells Human periodontal ligament (HPDL) cells were grown in a 6-well plate at a concentration of 5 ⁇ 10 5 cells/mL at a temperature of 37°C and 5% CO 2 . After culturing for 24 hours under culture conditions, treatment with steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) at concentrations of 0, 50, 100, 150, and 200 ⁇ g/mL for 6 hours and then treated with PG-LPS. Stimulation was performed for 12 hours. Then, after lysis with cell lysis buffer (RIPA buffer), centrifugation at 23,000 20 ⁇ g was loaded into each well and transferred to a PVDF membrane.
- EX steamed ginseng fruit concentrate
- EX powder steamed ginseng fruit concentrate powder
- steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) contains the antioxidant enzymes SOD, CAT and GPx lost from human periodontal ligament cells stimulated with PG-LPS. Protein expression was upregulated in a concentration-dependent manner.
- Periodontitis The main cause of periodontitis is bacteria present in the oral cavity, and periodontal disease occurs due to inflammatory progression due to the reaction of periodontal tissue due to mixed infection caused by several types of bacteria present in plaque.
- Porphyromonas gingivalis which belongs to the red complex, is known to be the most important cause of periodontal disease.
- gingivalis is a Gram-negative anaerobic bacterium that increases in number in the lesions of patients with periodontal disease, and is often found in the crevicular epithelium as periodontal disease progresses.
- gingivalis produces metabolites or toxins in the process of attaching to or infiltrating host tissues and cells, causing direct harm to periodontal tissue, but is also caused by cytokines produced in cells that react with P. gingivalis , and cytokines. Substances produced by reacting host cells further destroy periodontal tissue, thereby accelerating periodontitis. Therefore, we investigated the antibacterial effect of steamed ginseng fruit concentrate against P. gingivalis, a representative bacteria causing periodontitis.
- MIC Minimum Inhibitory Concentration
- P. gingivalis (KCTC 5352) The strain was distributed from the Biological Resources Center of the Jeonbuk Branch of the Korea Research Institute of Bioscience and Biotechnology. After injecting into TSA (Tryptic Soy Agar) hemin menadione medium at a concentration of 1 ⁇ 10 5 [CFU]/mL, steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) was added to 0, Treated at concentrations of 2.5, 5, 10, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, and 220 ⁇ g/mL and cultured under anaerobic conditions at 37°C. After completion of the culture, the MIC was analyzed by analyzing the absorbance at a wavelength of 600 nm using a microplate analyzer, and the results are shown in Figures 6 and 7.
- the Minimum Inhibitory Concentration refers to the lowest concentration of an antibacterial agent necessary to inhibit the visible growth of bacteria
- the Minimum Bicteriocidal Concentration (MBC) is the minimum concentration of an antibacterial agent that kills bacteria.
- Example 4.1 samples from the 160 to 220 ⁇ g/mL treatment group were re-cultivated to confirm the minimum bactericidal concentration (MBC) of the steamed ginseng fruit concentrate (EX) and the steamed ginseng fruit concentrate powder (EX powder) against P. gingivalis. And the results are shown in Figures 8 and 9. As shown in Figures 8 and 9, it was confirmed that the strain did not grow from 180 ⁇ g/mL in both steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder). Accordingly, it was confirmed that the minimum bactericidal concentration (MBC) of steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) against P. gingivalis was the same at 180 ⁇ g/mL.
- MBC minimum bactericidal concentration
- steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) were confirmed to exhibit antibacterial and sterilizing effects against P. gingivalis strains, the main causative bacteria causing periodontal disease, and these steamed ginseng fruits It is believed that the antibacterial and sterilizing effects of concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) will play an important role in controlling periodontitis along with the anti-inflammatory, osteoblast differentiation inducing, and antioxidant effects identified above.
- 20 g of the steamed ginseng fruit concentrate of the present invention was mixed with 175.9 g of lactose, 180 g of potato starch, and 32 g of colloidal silicic acid. A 10% gelatin solution was added to this mixture, then pulverized and passed through a 14 mesh sieve. This was dried and 160g of potato starch, 50g of talc, and 5g of magnesium stearate were added to make the resulting mixture into tablets.
- 20 g of the steamed ginseng fruit concentrate of the present invention was mixed with 50 g of dextrin, then the ingredients were mixed and spray dried according to a conventional powder manufacturing method to prepare a powder.
- 100 mg of steamed ginseng fruit concentrate, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate are mixed, then the above ingredients are mixed according to a typical capsule manufacturing method and filled into a gelatin capsule to prepare a capsule. did.
- 20g of steamed ginseng fruit concentrate of the present invention appropriate amount of vitamin mixture, 70 ⁇ g of vitamin A acetate, 1.0mg of vitamin E, 0.13mg of vitamin B1, 0.15mg of vitamin B2, 0.5mg of vitamin B6, 0.2mg of vitamin B12, 10mg of vitamin C, biotin 10 ⁇ g, nicotinic acid amide 1.7mg, folic acid 50 ⁇ g, calcium pantothenate 0.5mg, appropriate amount of mineral mixture, ferrous sulfate 1.75mg, zinc oxide 0.82mg, magnesium carbonate 25.3mg, potassium phosphate monobasic 15mg, calcium phosphate 255 mg, 90mg potassium citrate, 100mg calcium carbonate, and 24.8mg magnesium chloride were mixed to form granules, but it can be manufactured by modifying it into various dosage forms depending on the purpose.
- the composition ratio of the above vitamin and mineral mixture may be modified arbitrarily, and the above ingredients may be mixed according to a typical health
- a beverage was prepared by mixing 1 g of the steamed ginseng fruit concentrate of the present invention, 0.1 g of citric acid, 100 g of fructooligosaccharide, and 900 g of purified water and stirring, heating, filtering, sterilizing, and refrigerating according to a typical beverage production method.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition for preventing or treating oral disease, containing a steamed ginseng berry extract as an active ingredient. Particularly, the present invention inhibits the expression of inflammatory cytokines of IL-6, IL-1β or TNF-α in periodontal ligament cells, induces differentiation of osteoblasts and exhibits antioxidant activity, and thus can be effectively used in the prevention and treatment of oral diseases.
Description
본 발명은 증숙 인삼열매 추출물을 유효성분으로 포함하는 구강질환 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient.
구강질환은 구강 내에서 발생하는 질환으로, 치주질환(periodontal disease, 풍치)과 치아우식증(dental cavities, 충치) 등 누구에게나 발병할 수 있으며, 통증, 저작기능 장애, 치주조직의 파괴, 구취 및 시린이와 같은 다양한 증상을 유발하고 치아상실을 초래하는 주된 요인으로 알려져 있다.Oral diseases are diseases that occur within the oral cavity, and can affect anyone, including periodontal disease (periodontal disease) and dental caries (cavities), and can cause pain, masticatory dysfunction, destruction of periodontal tissue, bad breath, and coldness. It is known to be the main factor that causes various symptoms and causes tooth loss.
치주질환은 성인 10명 중 7명 이상이 이환되어 있는 매우 유병률이 높은 만성질환이다. 치주질환은 크게 치은염과 치주염으로 나뉘며, 잇몸 즉, 연조직에만 국한된 형태를 치은염이라 하고, 이러한 염증이 잇몸과 잇몸 뼈 주변까지 진행된 경우를 치주염이라고 한다.Periodontal disease is a chronic disease with a very high prevalence, affecting more than 7 out of 10 adults. Periodontal disease is largely divided into gingivitis and periodontitis. When the inflammation is limited to the gums, or soft tissue, it is called gingivitis, and when this inflammation progresses to the gums and gum bones, it is called periodontitis.
진지발리스와 같은 치주염균에 의한 복합적인 유발원인으로 발생되는 치주염은 치아지지구조의 염증과 동시에 치주인대의 파괴와 치조골의 소실을 초래하기 때문에, 항균 및 항염증, 조골세포 분화의 촉진 등의 복합적 치료 방법이 필요하다. 현재 치주염의 가장 효과적인 치료법은 약물치료와 외과적 수술을 병행하는 것이나 이러한 치료 방법은 치료 예후가 좋지 않고 환자에게 통증과 부작용을 유발할 수 있다. 또한 항균, 항염제 등 구강질환의 치료에 사용되는 약물은 근본적인 치주질환의 치료제가 아니며 장기복용에 따른 부작용을 동반하고 있다. 이에 따라 치주염 예방 및 치료를 위한 천연물 소재의 확보 및 생약/천연물 신소재 발굴이 필요한 실정이다.Periodontitis, which is caused by complex causes caused by periodontitis bacteria such as gingivalis, causes inflammation of the tooth-supporting structure and simultaneously causes destruction of the periodontal ligament and loss of alveolar bone, so it has complex antibacterial and anti-inflammatory properties, and promotion of osteoblast differentiation. A treatment method is needed. Currently, the most effective treatment for periodontitis is a combination of drug treatment and surgery, but this treatment method has a poor treatment prognosis and can cause pain and side effects in patients. In addition, drugs used to treat oral diseases, such as antibacterial and anti-inflammatory drugs, are not treatments for fundamental periodontal disease and are accompanied by side effects due to long-term use. Accordingly, there is a need to secure natural materials and discover new herbal medicine/natural materials for the prevention and treatment of periodontitis.
한편, 인삼의 열매는 4년생 인삼에서 5~7월에 열리는 희귀한 열매이다. 기존에는 단순히 인삼 씨앗으로만 인식되어 왔으나 미국, 일본, 한국 등 의학계의 임상실험 및 연구 결과를 통해 인삼의 사포닌인 진세노사이드(ginsenoside)가 다량 함유되어 있음이 밝혀졌다. 그러나 열매를 수확한 지 하루 만에 시들어버리는 인삼 열매의 특성상 단시간에 집중적인 수확을 필요로 하기 때문에 재배 및 관리에 어려움이 따르는 문제가 있었다.Meanwhile, ginseng fruit is a rare fruit that grows from May to July in 4-year-old ginseng. Previously, it was simply recognized as a ginseng seed, but through clinical trials and research results in the medical community in the United States, Japan, and Korea, it was revealed that it contains a large amount of ginsenoside, a saponin of ginseng. However, due to the nature of ginseng fruits, which wither within a day after harvesting, they require intensive harvesting in a short period of time, making cultivation and management difficult.
종래 기술로, 한국등록특허 제10-1394832호에는 인삼열매 추출물을 유효성분으로 함유하는 구강세균억제용 조성물이 기재되어 있으며, 한국공개특허 제10-2016-00065472호에는 인삼 열매의 과육 및 과피는 제거하고 종자만을 볶아 미세분말로 제조하는 인삼 열매의 종자 가공방법이 개시되어 있다. 그러나, 인삼 열매의 적절한 가공을 통해 인삼 열매의 이용률을 높이고 약효성분을 증강시켜 새로운 용도를 발굴하는 연구가 필요한 실정이다.As a prior art, Korean Patent No. 10-1394832 describes a composition for suppressing oral bacteria containing ginseng fruit extract as an active ingredient, and Korean Patent Publication No. 10-2016-00065472 describes the pulp and skin of ginseng fruit. A seed processing method of ginseng fruit is disclosed in which the seed is removed and only the seeds are roasted to produce a fine powder. However, research is needed to increase the utilization rate of ginseng fruits and enhance their medicinal properties through appropriate processing of ginseng fruits to discover new uses.
본 발명의 목적은 증숙 인삼열매 추출물을 유효성분으로 포함하는 구강질환 예방 또는 치료용 조성물을 제공하는 데 있다.The purpose of the present invention is to provide a composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient.
상기 과제의 해결을 위하여 본 발명은 증숙 인삼열매 추출물을 유효성분으로 포함하는 구강질환 예방 또는 치료용 조성물을 제공한다.In order to solve the above problems, the present invention provides a composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient.
상기 증숙 인삼열매 추출물은 농축된 형태의 농축물로 이용될 수 있으며, 상기 증숙 인삼열매 농축물은 증숙 인삼열매 농축액 또는 증숙 인삼열매 농축액을 동결건조한 파우더 형태로 이용될 수 있다.The steamed ginseng fruit extract can be used in a concentrated form, and the steamed ginseng fruit concentrate can be used in the form of a powder obtained by freeze-drying the steamed ginseng fruit concentrate or the steamed ginseng fruit concentrate.
상기 증숙 인삼열매 추출물은 인삼열매의 물, 저급알코올(메탄올, 에탄올, 프로판올, 부탄올), 저급알코올 수용액, 또는 유기용매(클로로포름, 에틸아세테이트, 디클로로메탄, 디메틸설폭사이드, 헥산등)의 추출 농축물을 100~130℃, 0.11~15㎫에서 4~12시간 동안 증숙한 증숙인삼열매 농축물을 포함하며, 상기 인삼열매의 추출 용매로 바람직하게는 물, 저급알코올(메탄올, 에탄올, 프로판올, 부탄올), 저급알코올 수용액이며, 더욱 바람직하게는 30~99% 에탄올이다.The steamed ginseng fruit extract is an extraction concentrate of ginseng fruit water, lower alcohol (methanol, ethanol, propanol, butanol), lower alcohol aqueous solution, or organic solvent (chloroform, ethyl acetate, dichloromethane, dimethyl sulfoxide, hexane, etc.) It contains a steamed ginseng fruit concentrate steamed at 100-130°C and 0.11-15 MPa for 4-12 hours, and the extraction solvent for the ginseng fruit is preferably water or lower alcohol (methanol, ethanol, propanol, butanol). , an aqueous solution of lower alcohol, more preferably 30 to 99% ethanol.
상기 증숙 인삼열매 추출물은 인삼열매의 50% 주정 추출물을 100~130℃ 온도, 0.11~15㎫ 압력에서 4~12시간 동안 증숙한 것일 수 있다.The steamed ginseng fruit extract may be obtained by steaming 50% alcohol extract of ginseng fruit at a temperature of 100 to 130°C and a pressure of 0.11 to 15 MPa for 4 to 12 hours.
본 발명은 상기 증숙 인삼열매 추출물은 고온고압에서 마이크로웨이브 처리하여 증숙한 증숙인삼열매 농축물일 수 있다. 상기 고온고압에서 마이크로웨이브 처리하여 증숙한 증숙인삼열매 농축물은 인삼열매의 물, 저급알코올(메탄올, 에탄올, 프로판올, 부탄올), 또는 저급알코올 수용액의 추출 농축물을 300~400W, 2.5~3.5㎫, 110~130℃, 및 30~90분 동안 고온고압에서 마이크로웨이브 처리하여 증숙한 증숙인삼열매 농축물이다.In the present invention, the steamed ginseng fruit extract may be a steamed ginseng fruit concentrate steamed by microwave treatment at high temperature and high pressure. The steamed ginseng fruit concentrate steamed by microwave treatment at high temperature and high pressure is extracted from ginseng fruit water, lower alcohol (methanol, ethanol, propanol, butanol), or lower alcohol aqueous solution at 300 to 400 W, 2.5 to 3.5 MPa. , It is a steamed ginseng fruit concentrate steamed by microwave treatment at 110~130℃, and high temperature and pressure for 30~90 minutes.
본 발명은 상기 고온고압으로 증숙 또는 고온고압에서 마이크로웨이브 처리하여 증숙한 증숙인삼열매 농축물은 활성성분인 진세노사이드 Rg6 0.5~2중량%, 진세노사이드 Rg4 0.5~2중량%, 및 진세노사이드 Rh4 0.5~5중량%를 포함할 수 있다.In the present invention, the steamed ginseng fruit concentrate steamed at high temperature and pressure or by microwave treatment at high temperature and pressure contains the active ingredients 0.5 to 2% by weight of ginsenoside Rg6, 0.5 to 2% by weight of ginsenoside Rg4, and ginsenoside. It may contain 0.5 to 5% by weight of side Rh4.
본 발명에서 구강질환은 치아우식증, 치주염 또는 치은염일 수 있다.In the present invention, the oral disease may be dental caries, periodontitis, or gingivitis.
본 발명에 있어서 “치아 우식증(dental cavities)”이란 치아면에 서식하는 세균으로 인한 감염성 질환으로서, 충치라고도 하며 구체적으로 치아의 머리 부분 표면을 덮고 있고, 치아 상아질을 보호하는 유백색의 반투명하고 단단한 물질인 치아 법랑질 또는 에나멜질이 입 안에 서식하는 구강병원균에 의해 설탕, 전분 등의 분해 중 생성되는 산에 의해 손상되어 발생한다.In the present invention, “dental cavities” refers to an infectious disease caused by bacteria living on the surface of teeth. Also called cavities, it is specifically a milky-white, translucent, hard substance that covers the surface of the head of the tooth and protects the dentin of the tooth. It occurs when tooth enamel or enamel is damaged by acids produced during the decomposition of sugar, starch, etc. by oral pathogens that live in the mouth.
본 발명에 있어서 “치주염(periodontitis)”은 치아를 받치고 있는 치은과 치주인대 및 골조직에 염증이 생기는 질환이다.In the present invention, “periodontitis” is a disease in which inflammation occurs in the gingiva, periodontal ligament, and bone tissue that support the teeth.
본 발명에 있어서 “치은염(gingivitis)”은 잇몸 즉, 연조직에만 국한된 형태의 치주 질환이다.In the present invention, “gingivitis” is a form of periodontal disease limited to the gums, i.e., soft tissue.
치주염, 또는 치은염 등의 치주질환을 일으키는 원인균으로, 구체적으로는 악티노바실루스 악티노마이세템코미탄스 (Actinobacillus actinomycetemcomitans), 포피로모나스 진지발리스(Porphyromonas gingivalis), 타네렐라 포르시시아(Tannerella forsythia), 트레포네마 덴티콜라 (Treponema denticola) 및 푸소박테리움 누클리아툼(Fusobacterium nucleatum)으로 이루어진 군으로부터 선택된 1종 이상의 균일 수 있으며, 보다 구체적으로는 포피로모나스 진지발리스일 수 있다.Bacteria that cause periodontal diseases such as periodontitis or gingivitis, specifically Actinobacillus actinomycetemcomitans , Porphyromonas gingivalis , and Tannerella forsythia. , Treponema denticola and Fusobacterium nucleatum may be one or more species selected from the group consisting of, and more specifically, Porphyromonas gingivalis.
상기 포피로모나스 진지발리스는 박테로이드(Bacteroide) 유연균의 일종으로 그람음성균이고, 혐기성균이며, 치주질환이 발생한 구강 내에서 발견되며, 그 외에도 위장관 상부, 호흡기 및 결장에서도 발견된다. 만성 치주질환 환자는 상기 균의 콜라게네이즈 효소에 의해 콜라겐이 분해되며, 상기 균은 치은 섬유아세포에 침입할 수 있으며, 상당한 농도의 항생제 하에서도 생존할 수 있다. 또한, 상기 균은 치은상피세포에 침입하여 장시간 생존할 수 있다.The Porphyromonas gingivalis is a type of Bacteroide soft bacteria, a Gram-negative bacterium, an anaerobic bacterium, and is found in the oral cavity where periodontal disease occurs, and is also found in the upper gastrointestinal tract, respiratory tract, and colon. In patients with chronic periodontal disease, collagen is decomposed by the collagenase enzyme of the bacteria, and the bacteria can invade gingival fibroblasts and survive even under high concentrations of antibiotics. Additionally, the bacteria can invade gingival epithelial cells and survive for a long time.
본 발명의 증숙 인삼열매 추출물을 유효성분으로 포함하는 구강질환 예방 또는 치료용 조성물은 치주질환을 일으키는 원인균에 대한 항균효과를 가지며, 특히 포르피로모나스 진지발리스(Porphyromonas gingivalis) 균주에 대한 항균 효과가 있는 것을 특징으로 한다.The composition for preventing or treating oral diseases containing the steamed ginseng fruit extract of the present invention as an active ingredient has an antibacterial effect against the causative bacteria that cause periodontal disease, and in particular has an antibacterial effect against the Porphyromonas gingivalis strain. It is characterized by having
본 발명의 인삼열매는 고려인삼(Panax ginseng), 미국인삼(Panax quinquefolius), 전칠삼(삼칠삼; Panax notoginseng), 죽절삼(Panax japonicus), 삼엽삼(미국왜삼; Panax trifolius), 히말라야삼(Panax pseudoginseng) 또는 베트남삼 (Panax vietnamensis)의 열매를 사용할 수 있으나, 이에 한정하는 것은 아니다.The ginseng fruit of the present invention is Korean ginseng ( Panax ginseng ), American ginseng ( Panax quinquefolius ), Panax notoginseng ( Panax notoginseng ), Panax japonicus , trifoliate ginseng (American ginseng; Panax trifolius ), and Himalayan ginseng ( Panax ). pseudoginseng ) or Vietnamese ginseng ( Panax vietnamensis ) fruits can be used, but are not limited to these.
본 발명의 증숙 인삼열매 추출물을 유효성분으로 포함하는 구강질환 예방 또는 치료용 조성물은 치주인대세포 등에서 IL-6, IL-1β 또는 TNF-α의 염증성 사이토카인의 발현을 억제할 수 있다. 또한 상기 조성물은 치주인대세포에서 조골세포의 분화를 유도할 수 있으며, 상기 조골세포의 분화 유도는 알칼라인 포스파타제(alkaline phosphatase, ALP) 또는 오스테오칼신(osteocalcin, OCN)의 발현을 증가시키거나 매트릭스 메탈로프로티나제(Matrix metalloproteinase, MMP)의 발현을 억제하는 것일 수 있다.The composition for preventing or treating oral diseases containing the steamed ginseng fruit extract of the present invention as an active ingredient can inhibit the expression of inflammatory cytokines such as IL-6, IL-1β or TNF-α in periodontal ligament cells. In addition, the composition can induce differentiation of osteoblasts from periodontal ligament cells, and the induction of differentiation of osteoblasts increases the expression of alkaline phosphatase (ALP) or osteocalcin (OCN) or matrix metalloproteinase. It may be inhibiting the expression of matrix metalloproteinase (MMP).
본 발명의 증숙 인삼열매 추출물을 유효성분으로 포함하는 구강질환 예방 또는 치료용 조성물은 치주인대세포에서 항산화 활성을 통하여 구강질환을 예방 또는 치료할 수 있다.The composition for preventing or treating oral diseases containing the steamed ginseng fruit extract of the present invention as an active ingredient can prevent or treat oral diseases through antioxidant activity in periodontal ligament cells.
상기 항산화 활성은 치주인대세포 등에서 초과산화물 불균등화효소(Superoxide dismutase, SOD), 카탈라제(Catalase, CAT) 또는 글루타티온 과산화효소(Glutathione Peroxidase, GPx)의 발현을 증가시킴으로써 나타날 수 있으며, 활성산소종(ROS)의 생성을 억제한다.The antioxidant activity can be shown by increasing the expression of superoxide dismutase (SOD), catalase (CAT), or glutathione peroxidase (GPx) in periodontal ligament cells, etc., and reactive oxygen species (ROS) ) inhibits the production of
본 발명에 따른 조성물은 약학 조성물로 제공될 수 있으며, 일반적으로 사용되는 약학적으로 허용 가능한 담체와 함께 적합한 형태로 제형화될 수 있다. “약학적으로 허용 가능”이란 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 위장 장애, 현기증 등과 같은 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 조성물을 말한다. 또한, 상기 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The composition according to the present invention can be provided as a pharmaceutical composition and can be formulated in a suitable form with a commonly used pharmaceutically acceptable carrier. “Pharmaceutically acceptable” refers to a composition that is physiologically acceptable and does not typically cause allergic or similar reactions such as gastrointestinal upset, dizziness, etc. when administered to humans. In addition, the composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods.
바람직하게 본 발명의 조성물은 치약, 구강세정제, 구강청정제, 껌, 캔디류, 구강스프레이, 구강용 젤, 구강용 연고제, 구강용 바니쉬, 잇몸 마사지 크림 및 구강용 패치로 이루어진 군으로부터 1이상 선택되는 형태로 제형화할 수 있다.Preferably, the composition of the present invention is in the form of one or more selected from the group consisting of toothpaste, mouthwash, mouthwash, gum, candy, oral spray, oral gel, oral ointment, oral varnish, gum massage cream, and oral patch. It can be formulated as:
상기 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로즈, 수크로스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아라비아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미결정셀룰로오스, 폴리비닐 피롤리돈, 물, 파라옥시벤조산메틸, 파라옥시벤조산프로필, 탈크, 스테아르산마그네슘 및 광물유를 포함할 수 있으나, 이에 한정되는 것은 아니다. 제제화할 경우에는 보통 사용하는 충진제, 안정화제, 결합제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 진세노사이드에 적어도 하나 이상의 부형제, 예를 들면, 전분, 미결정셀룰로오스, 수크로스 또는 락토오스, 저치환도히드록시프로필셀룰로오스, 히프로멜로오스 등을 섞어 조제된다. 또한 단순한 부형제 이외에 스테아르산마그네슘, 탈크 같은 활택제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 유동파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤, 젤라틴 등이 사용될 수 있다. 비경구 투여용 제형으로 제제화하기 위하여 상기 진세노사이드 또는 이의 약학적으로 허용되는 염을 멸균되거나 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 또는 완충제 등의 보조제, 및 기타 치료적으로 유용한 물질과 함께 물에 혼합하여 용액 또는 현탁액으로 제조하고, 이를 앰플 또는 바이알 단위 투여형으로 제조할 수 있다.Carriers, excipients, and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, and methyl. It may include, but is not limited to, cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl paraoxybenzoate, propyl paraoxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, stabilizers, binders, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the ginsenoside of the present invention with at least one excipient, such as starch, microcrystalline cellulose, sucrose or It is prepared by mixing lactose, low-substituted hydroxypropyl cellulose, and hypromellose. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurel, glycerol, gelatin, etc. can be used. In order to formulate a formulation for parenteral administration, the ginsenoside or a pharmaceutically acceptable salt thereof is sterilized or added with preservatives, stabilizers, wetting agents or emulsification accelerators, auxiliaries such as salts or buffers for osmotic pressure adjustment, and other therapeutic agents. It can be prepared as a solution or suspension by mixing it in water with useful substances, and it can be prepared in ampoule or vial unit dosage form.
상기 약학 조성물은 쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여될 수 있다. 투여량은 치료받을 대상의 연령, 성별, 체중, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여시간, 투여경로, 약물의 흡수, 분포 및 배설률, 사용되는 다른 약물의 종류 및 처방자의 판단 등에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.01㎎/㎏/일 내지 대략 5000㎎/㎏/일의 범위이다. 더 바람직한 투여량은 1㎎/㎏/일 내지 500㎎/㎏/일이다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The pharmaceutical composition can be administered to mammals such as rats, livestock, and humans through various routes. All modes of administration are contemplated, for example, oral, rectal or by intravenous, intramuscular, subcutaneous, intrathecal or intracerebrovascular injection. The dosage is determined by the age, gender, and weight of the subject to be treated, the specific disease or pathological state to be treated, the severity of the disease or pathological state, administration time, route of administration, absorption, distribution and excretion rate of the drug, types of other drugs used, and the prescriber's It will vary depending on judgment, etc. Dosage determinations based on these factors are within the level of one skilled in the art, and dosages generally range from 0.01 mg/kg/day to approximately 5000 mg/kg/day. A more preferred dosage is 1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
또 다른 일면에 있어서, 본 발명은 증숙인삼열매 농축물을 포함하는 구강질환 예방 또는 개선용 건강기능식품을 제공한다.In another aspect, the present invention provides a health functional food for preventing or improving oral diseases containing a steamed ginseng fruit concentrate.
상기 건강기능식품은 유용한 기능성을 가진 원료나 성분을 사용하여 제조 또는 가공한 식품을 지칭하는 것으로, 예를 들어 건강보조식품, 기능성 식품, 영양제, 보조제 등을 모두 포함한다.The health functional food refers to food manufactured or processed using raw materials or ingredients with useful functionality, and includes, for example, health supplements, functional foods, nutrients, supplements, etc.
상기 증숙인삼열매 농축물은 전체 건강기능식품 총 중량에 대하여 바람직하게는 0.001중량% 내지 50중량%, 더 바람직하게는 0.001중량% 내지 40중량%, 가장 바람직하게는 0.001중량% 내지 30중량%로 하여 첨가될 수 있다. 상기 첨가량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The steamed ginseng fruit concentrate is preferably 0.001% by weight to 50% by weight, more preferably 0.001% by weight to 40% by weight, and most preferably 0.001% by weight to 30% by weight, based on the total weight of the entire health functional food. It can be added. The above addition amount does not limit the scope of the present invention in any way.
본 발명의 건강기능식품은 정제, 캡슐제, 환제 및 액제 등의 형태를 포함하며, 본 발명 진세노사이드를 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제 등이 있다.The health functional food of the present invention includes forms such as tablets, capsules, pills, and liquids. Foods to which the ginsenoside of the present invention can be added include, for example, various foods, beverages, gum, tea, and vitamins. There are combination drugs, etc.
본 발명은 증숙 인삼열매 추출물을 유효성분으로 포함하는 구강질환 예방 또는 치료용 조성물에 관한 것으로, 구체적으로는 치주인대세포에서 IL-6, IL-1β 또는 TNF-α의 염증성 사이토카인의 발현을 억제하고, 조골세포의 분화를 유도하며, 항산화 활성을 나타내어 구강질환의 예방과 치료에 유용하게 사용 가능하다.The present invention relates to a composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient, and specifically, inhibits the expression of inflammatory cytokines such as IL-6, IL-1β or TNF-α in periodontal ligament cells. It induces the differentiation of osteoblasts and exhibits antioxidant activity, making it useful for the prevention and treatment of oral diseases.
도 1은 PS-LPS로 처리한 인간 치주인대세포에서 본 발명에 따른 증숙 인삼열매 농축액 및 증숙 인삼열매 농축액 파우더의 염증성 사이토카인의 발현에 미치는 효과를 나타낸 그래프이다.Figure 1 is a graph showing the effect of steamed ginseng fruit concentrate and steamed ginseng fruit concentrate powder according to the present invention on the expression of inflammatory cytokines in human periodontal ligament cells treated with PS-LPS.
도 2는 PS-LPS로 처리한 인간 치주인대세포에서 본 발명에 따른 증숙 인삼열매 농축액의 조골세포 분화에 미치는 효과를 나타낸 그래프이다.Figure 2 is a graph showing the effect of the steamed ginseng fruit concentrate according to the present invention on osteoblast differentiation in human periodontal ligament cells treated with PS-LPS.
도 3은 PS-LPS로 처리한 인간 치주인대세포에서 본 발명에 따른 증숙 인삼열매 농축액 파우더의 조골세포 분화에 미치는 효과를 나타낸 그래프이다.Figure 3 is a graph showing the effect of the steamed ginseng fruit concentrate powder according to the present invention on osteoblast differentiation in human periodontal ligament cells treated with PS-LPS.
도 4는 PS-LPS로 처리한 인간 치주인대세포에서 본 발명에 따른 증숙 인삼열매 농축액의 항산화 활성에 미치는 효과를 나타낸 그래프이다.Figure 4 is a graph showing the effect on the antioxidant activity of the steamed ginseng fruit concentrate according to the present invention in human periodontal ligament cells treated with PS-LPS.
도 5는 PS-LPS로 처리한 인간 치주인대세포에서 본 발명에 따른 증숙 인삼열매 농축액 파우더의 항산화 활성에 미치는 효과를 나타낸 그래프이다.Figure 5 is a graph showing the effect on the antioxidant activity of the steamed ginseng fruit concentrate powder according to the present invention in human periodontal ligament cells treated with PS-LPS.
도 6은 본 발명에 따른 증숙 인삼열매 농축액의 포피로모나스 진지발리스(Porphyromonas gingivalis)에 대한 MIC test를 보여주는 결과이다.Figure 6 is a result showing the MIC test against Porphyromonas gingivalis of the steamed ginseng fruit concentrate according to the present invention.
도 7은 본 발명에 따른 증숙 인삼열매 농축액 파우더의 포피로모나스 진지발리스(Porphyromonas gingivalis)에 대한 MIC test를 보여주는 결과이다.Figure 7 shows the results of an MIC test against Porphyromonas gingivalis of the steamed ginseng fruit concentrate powder according to the present invention.
도 8은 본 발명에 따른 증숙 인삼열매 농축액의 포피로모나스 진지발리스(Porphyromonas gingivalis)에 대한 MBC test를 보여주는 결과이다.Figure 8 shows the results of the MBC test for Porphyromonas gingivalis of the steamed ginseng fruit concentrate according to the present invention.
도 9는 본 발명에 따른 증숙 인삼열매 농축액 파우더의 포피로모나스 진지발리스(Porphyromonas gingivalis)에 대한 MBC test를 보여주는 결과이다.Figure 9 is a result showing the MBC test for Porphyromonas gingivalis of the steamed ginseng fruit concentrate powder according to the present invention.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있으며, 여기서 소개되는 내용은 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다.Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms, and the content introduced here is provided to sufficiently convey the idea of the present invention.
<실시예 1. 고온고압으로 증숙한 증숙인삼열매 농축물 제조><Example 1. Preparation of steamed ginseng fruit concentrate steamed at high temperature and high pressure>
인삼열매 50kg에 50% 주정 600kg을 첨가하여 85℃ 온도에서 6시간 동안 2회 추출하였다. 그 다음 상기 추출물을 여과하여 70brix로 농축하였다. 이를 121℃ 온도 및 0.13㎫ 압력에서 4시간 동안 증숙하여 증숙인삼열매 농축물을 얻었다. 하기 표 1에 70brix로 농축한 증숙인삼열매 농축물 내의 진세노사이드 성분 종류와 그 함량을 정리하였다.600kg of 50% alcohol was added to 50kg of ginseng fruit and extracted twice for 6 hours at 85°C. The extract was then filtered and concentrated to 70 brix. This was steamed at a temperature of 121°C and a pressure of 0.13 MPa for 4 hours to obtain a steamed ginseng fruit concentrate. Table 1 below summarizes the types and contents of ginsenoside components in the steamed ginseng fruit concentrate concentrated to 70 brix.
<실시예 2. 고온고압에서 마이크로웨이브 증숙처리한 증숙인삼열매 농축물 제조><Example 2. Preparation of steamed ginseng fruit concentrate by microwave steaming at high temperature and high pressure>
인삼열매 50kg에 50% 주정 600kg을 첨가하여 85℃ 온도에서 6시간 동안 2회 추출하였다. 그 다음 상기 추출물을 여과하여 70brix로 농축하였다. 이를 400W, 3.0㎫ 조건에서 130℃로 60분 동안 마이크로웨이브를 조사하여 마이크로웨이브 증숙처리한 증숙인삼열매 농축물을 얻었다. 하기 표 1에 고온고압에서 마이크로웨이브를 조사하여 중숙처리한 증숙인삼열매 농축물 내의 진세노사이드 성분 종류와 그 함량을 정리하였다.600kg of 50% alcohol was added to 50kg of ginseng fruit and extracted twice for 6 hours at 85°C. The extract was then filtered and concentrated to 70 brix. This was irradiated with a microwave at 130°C for 60 minutes under conditions of 400 W and 3.0 MPa to obtain a steamed ginseng fruit concentrate subjected to microwave steaming. Table 1 below summarizes the types and contents of ginsenoside components in the steamed ginseng fruit concentrate that was medium-ripened by irradiating microwaves at high temperature and pressure.
<비교예 1. 증숙하지 않은 인삼열매 농축물 제조><Comparative Example 1. Preparation of non-steamed ginseng fruit concentrate>
인삼열매 50kg에 50% 주정 600kg을 첨가하여 85℃ 온도에서 6시간 동안 2회 추출하였다. 그다음 상기 추출물을 여과하여 70brix로 농축하여 인삼열매 농축물을 얻었다. 하기 표 1에 증숙과정을 거치지 않고 70brix로 농축한 인삼열매 농축물 내의 진세노사이드 성분 종류와 그 함량을 정리하였다.600kg of 50% alcohol was added to 50kg of ginseng fruit and extracted twice for 6 hours at 85°C. Then, the extract was filtered and concentrated to 70 brix to obtain ginseng fruit concentrate. Table 1 below summarizes the types and contents of ginsenoside components in ginseng fruit concentrate concentrated to 70 brix without undergoing a steaming process.
진세노사이드Ginsenoside |
비교예 1. 증숙 처리전 인삼열매농축물 중 진세노사이드 함량 (mg/g) Comparative Example 1. Ginseng fruit concentrate before steaming Ginsenoside content (mg/g) |
실시예 1. 고온고압으로 증숙한 인삼열매농축물 중 진세노사이드 함량 (mg/g) Example 1. Ginsenoside content in ginseng fruit concentrate steamed at high temperature and pressure (mg/g) |
실시예 2. 고온고압에서 마이크로웨이브 증숙처리한 인삼열매농축물 중 진세노사이드 함량 (mg/g) Example 2. Ginseng fruit concentrate processed by microwave steaming at high temperature and pressure Ginsenoside content (mg/g) |
Re+Rg1Re+Rg1 | 64.9364.93 | 5.615.61 | 00 |
Rb1Rb1 | 21.9721.97 | 4.884.88 | 00 |
RcRc | 17.6417.64 | 5.715.71 | 00 |
Rb2Rb2 | 15.6815.68 | 6.716.71 | 00 |
RdRd | 16.2316.23 | 13.2113.21 | 00 |
Rg2-SRg2-S | 2.872.87 | 14.1914.19 | 7.377.37 |
Rh1-SRh1- |
00 | 1.371.37 | 3.043.04 |
Rg2-RRg2- |
00 | 5.015.01 | 3.983.98 |
Rh1-RRh1- |
00 | 1.031.03 | 2.352.35 |
Rg6Rg6 | 00 | 10.3810.38 | 10.1510.15 |
Rg4 |
00 | 11.3111.31 | 10.9910.99 |
Rh4 |
00 | 11.9811.98 | 30.0830.08 |
Rg3-SRg3- |
00 | 7.787.78 | 9.189.18 |
Rg3-RRg3- |
00 | 7.187.18 | 9.339.33 |
Rk1 |
00 | 6.036.03 | 14.4214.42 |
Rg5 |
00 | 8.668.66 | 19.4419.44 |
총량total amount | 139.32139.32 | 121.04121.04 | 120.33120.33 |
상기 표 1에 인삼열매 농축 후 처리에 따른 진세노사이드 성분 종류와 그 함량을 정리하였다.증숙 전의 인삼열매 농축물(비교예 1)은 진세노사이드 Re+Rg1을 많이 함유하는 반면, 고온고압으로 증숙한 인삼열매 농축물(실시예 1)에서는 증숙 전에 존재하던 진세노사이드 성분들이(Re+Rg1, Rb1, Rc, Rb2, Rd) 줄어들고 저분자의 진세노사이드 Rg6, Rg4, Rh4, Rg2, Rh1, Rg3, Rk1, Rg5 등이 생성되었으며, 특히 진세노사이드 Rg6, Rg4 및 Rh4 성분이 현저히 증가하는 것을 확인할 수 있었다. 또한 고온고압에서 마이크로웨이브 증숙한 인삼열매 농축물(실시예 2)에서는 증숙 전에 존재하던 진세노사이드 성분들은 완전히 소멸하였으며, 진세노사이드 Rg6, Rg4 및 Rh4 성분이 현저히 강화된 증숙인삼열매 농축물을 만들 수 있었다.Table 1 above summarizes the types of ginsenoside components and their contents according to the treatment after concentrating ginseng fruit. While the ginseng fruit concentrate before steaming (Comparative Example 1) contains a lot of ginsenoside Re+Rg1, it is concentrated at high temperature and pressure. In the steamed ginseng fruit concentrate (Example 1), the ginsenoside components (Re+Rg1, Rb1, Rc, Rb2, Rd) present before steaming were reduced, and low molecular weight ginsenosides Rg6, Rg4, Rh4, Rg2, Rh1, Rg3, Rk1, Rg5, etc. were produced, and in particular, it was confirmed that ginsenoside Rg6, Rg4, and Rh4 components were significantly increased. In addition, in the ginseng fruit concentrate (Example 2) that was microwave-steamed at high temperature and pressure, the ginsenoside components that existed before steaming were completely destroyed, and the steamed ginseng fruit concentrate with significantly enhanced ginsenoside Rg6, Rg4, and Rh4 components was obtained. I was able to make it.
이에 따라 이후 실험은 실시예 2에 따른 고온고압에서 증숙처리한 인삼열매 농축물을 실험에 사용하였으며, 고온고압으로 증숙처리한 증숙인삼열매 농축액 및 보관과 유통에 용이하도록 상기 증숙 인삼열매 농축액을 동결건조한 증숙 인삼열매 농축액 파우더를 사용하여 실시하였다.Accordingly, in the subsequent experiments, the ginseng fruit concentrate steamed at high temperature and high pressure according to Example 2 was used, and the steamed ginseng fruit concentrate steamed at high temperature and high pressure was frozen to facilitate storage and distribution. This was conducted using dried steamed ginseng fruit concentrate powder.
<실험예 1. 증숙 인삼열매 농축물의 항염 효과 확인><Experimental Example 1. Confirmation of anti-inflammatory effect of steamed ginseng fruit concentrate>
구강 세균 중 대표적인 치주질환 병원균(periodontal pathogens)에는 포르피로모나스 진지발리스(Porphyromonas gingivalis), 트레포네마 덴티콜라(Treponema denticola, Prevotella intermedia), 아그레가티박터 액티노미세템코미탄스(Aggregatibacter actinomycetemcomitans) 등이 있으며, 이들 미생물이 형성하는 lipopolysaccharides (LPS) 내 독소 혹은 대사산물은 조직과 면역세포에서부터 전염증성 사이토카인(proinflammatory cytokine)의 분비를 증가시킨다. 이러한 전염증성 사이토카인은 치주조직을 손상시키며 매트릭스 메탈로프로테나제(Matrix metalloproteinase, MMP)와 같은 효소 활성을 유도함으로써 결합조직 파괴하여 치주조직을 손상시킨다. 따라서 치주염에서 이러한 전염증성 사이토카인의 억제는 치주염 억제에 중요한 치료전략이다. 이에 따라 Porphyromonas gingivalis-LPS (PG-LPS)로 자극된 인간치주인대세포에서 치주염증의 대표적 염증성 사이토카인 조절에 증숙 인삼열매 농축물이 미치는 효과를 평가하였다.Representative periodontal pathogens among oral bacteria include Porphyromonas gingivalis, Treponema denticola, Prevotella intermedia , and Aggregatibacter actinomycetemcomitans . The lipopolysaccharides (LPS) endotoxins or metabolites formed by these microorganisms increase the secretion of proinflammatory cytokines from tissues and immune cells. These pro-inflammatory cytokines damage periodontal tissue and destroy connective tissue by inducing enzyme activity such as matrix metalloproteinase (MMP). Therefore, inhibition of these pro-inflammatory cytokines in periodontitis is an important treatment strategy for suppressing periodontitis. Accordingly, the effect of steamed ginseng fruit concentrate on regulating representative inflammatory cytokines of periodontal inflammation in human periodontal ligament cells stimulated with Porphyromonas gingivalis -LPS (PG-LPS) was evaluated.
인간 치주인대세포는 경북대학교 치과대학에서 기증받아 사용하였다. 인간 치주인대 (Human preiodontal ligament, HPDL) 세포를 5×103 cell/mL의 농도로 96-well plate에 37 ℃의 온도, 5% CO2
배양조건하에 24시간 배양하였다. 이후, 증숙 인삼열매 농축액 또는 증숙 인삼열매 농축액 파우더를 0, 50, 100, 150 및 200 μg/mL의 농도로 처리하고 37 ℃의 온도, 5% CO2
배양조건하에 6시간 배양하였다. 이후 PG-LPS로 6시간 자극한 다음, TRIzol/chloroform reagent를 이용하여 추출된 총 cDNA를 나노드롭(nanodrop)으로 정량 후 PrimeScript-RT reagent kit (SYBR Premix Ex Taq)를 이용하여 염증성 사이토카인 IL-6, IL-1β 및 TNFα 유전자를 증폭하여 분석하였다. 각 표적 유전자의 역치 (Ct) 값을 housekeeping gene인 GAPDH 수치로 정규화하고 그 결과를 도 1에 나타내었다.Human periodontal ligament cells were donated and used by Kyungpook National University College of Dentistry. Human preiodontal ligament (HPDL) cells were cultured in a 96-well plate at a concentration of 5×10 3 cell/mL at a temperature of 37°C and 5% CO 2 . Cultured for 24 hours under culture conditions. Afterwards, the steamed ginseng fruit concentrate or steamed ginseng fruit concentrate powder was treated at concentrations of 0, 50, 100, 150, and 200 μg/mL and incubated at a temperature of 37°C and 5% CO 2. Cultured for 6 hours under culture conditions. After stimulation with PG-LPS for 6 hours, the total cDNA extracted using TRIzol/chloroform reagent was quantified using nanodrop, and the inflammatory cytokine IL- was extracted using PrimeScript-RT reagent kit (SYBR Premix Ex Taq). 6, IL-1β and TNFα genes were amplified and analyzed. The threshold (Ct) value of each target gene was normalized to the level of GAPDH, a housekeeping gene, and the results are shown in Figure 1.
도 1에서 보는 바와 같이, 증숙 인삼열매 농축액 또는 증숙 인삼열매 농축액 파우더 모두 농도의존적으로 IL-6, IL-1β 및 TNFα의 발현을 억제하였다. 특히 증숙 인삼열매 농축액 파우더는 증숙 인삼열매 농축액보다 더 낮은 농도에서 IL-6의 발현을 유의하게 하향 조절하였다. 이와 같이, 증숙 인삼열매 농축액 또는 증숙 인삼열매 농축액 파우더은 인간 치주인대세포에서 PG-LPS에 의해 증가된 염증성 매개인자와 사이토카인을 효과적으로 하향 조절하여 치주염증 억제효과를 나타낼 수 있음을 확인하였다.As shown in Figure 1, both steamed ginseng fruit concentrate and steamed ginseng fruit concentrate powder suppressed the expression of IL-6, IL-1β, and TNFα in a concentration-dependent manner. In particular, steamed ginseng fruit concentrate powder significantly down-regulated the expression of IL-6 at a lower concentration than steamed ginseng fruit concentrate. In this way, it was confirmed that steamed ginseng fruit concentrate or steamed ginseng fruit concentrate powder can effectively downregulate inflammatory mediators and cytokines increased by PG-LPS in human periodontal ligament cells, thereby exhibiting an inhibitory effect on periodontal inflammation.
<실험예 2. 증숙 인삼열매 농축물의 조골세포 분화 유도 효과 확인><Experimental Example 2. Confirmation of osteoblast differentiation inducing effect of steamed ginseng fruit concentrate>
초기 치은염이 만성염증으로 장기화되면 잇몸뿐만 아니라 잇몸 아래 치조골까지 침식하게 되며 이를 치주염이라 한다. 일단 치조골이 소실되면 원래 상태로의 회복이 어려우며, 치주염이 진행될수록 치조골 소실이 증가하게 된다. 골세포의 활성 지표로 활용되는 알칼라인 포스파타제(alkaline phosphatase, ALP)와 오스테오칼신(osteocalcin, OCN)의 발현은 인간 치주인대세포의 치조골 형성에 중요한 요인으로 알려져 있으며, 이에 따라 치주염으로 손실된 이들 골세포 분화 활성지표의 회복은 치주염 치료에 또 하나의 중요한 치료전략이 되고 있다. 따라서 PG-LPS로 자극된 인간 치주인대세포에서 증숙 인삼열매 농축물에 의한 조골분화능을 평가하여 인간 치주인대세포의 재생에 미치는 영향을 평가하였다.If initial gingivitis becomes chronic inflammation and becomes prolonged, not only the gums but also the alveolar bone below the gums erode, which is called periodontitis. Once alveolar bone is lost, it is difficult to restore it to its original state, and as periodontitis progresses, alveolar bone loss increases. The expression of alkaline phosphatase (ALP) and osteocalcin (OCN), which are used as indicators of the activity of osteocytes, are known to be important factors in the formation of alveolar bone in human periodontal ligament cells, and thus the differentiation of these osteocytes lost due to periodontitis. Restoration of activity indicators has become another important treatment strategy in the treatment of periodontitis. Therefore, the osteoblastic differentiation capacity of steamed ginseng fruit concentrate was evaluated in human periodontal ligament cells stimulated with PG-LPS, and its effect on the regeneration of human periodontal ligament cells was evaluated.
2.1 인간 치주인대세포의 조골분화 유도효과 평가2.1 Evaluation of osteoblast differentiation induction effect of human periodontal ligament cells
인간 치주인대 (Human preiodontal ligament, HPDL) 세포를 5×102 cell/mL의 농도로 24-well plate에 37 ℃의 온도, 5% CO2
배양조건하에 24시간 배양하였다. 그 후 배양액을 제거한 다음, 10% fetal bovine serum, 100U/ml penicilline, 100 μg/mL streptomycin, 50 μg/mL ascorbic acid, 10 mM β-glycerophosphate가 함유된 α-MEM으로 배양액을 교체하여 조골분화를 유도하였다. 조골분화 유도와 함께 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)를 0, 50, 100, 150 및 200 μg/mL의 농도로 처리한 후, PG-LPS (1 μg/mL)을 처리 후 37 ℃의 온도, 5% CO2
배양조건하에 14일간 배양하였다. 배양 종료 후 세포를 4 % formaldehyde로 30분 동안 고정하고 0.1 % Alizarin Red S (pH 4.3)로 1시간 염색 후 실온에서 30 분 동안 탈이온수로 세척한 다음, 현미경을 통해 광물화된 결절(mineralized nodules) 형성을 확인 후 10% 세틸피리디늄 클로라이드(cetylpyridinium chloride) 400 uL로 녹여 흡광 (570nm)을 측정하여 도 2 및 도 3에 나타내었다.Human periodontal ligament (HPDL) cells were grown in a 24-well plate at a concentration of 5×10 2 cell/mL at a temperature of 37°C and 5% CO 2 Cultured for 24 hours under culture conditions. After removing the culture medium, the culture medium was replaced with α-MEM containing 10% fetal bovine serum, 100U/ml penicilline, 100 μg/mL streptomycin, 50 μg/mL ascorbic acid, and 10 mM β-glycerophosphate to promote osteoblast differentiation. induced. After inducing osteoblastic differentiation and treating steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) at concentrations of 0, 50, 100, 150, and 200 μg/mL, PG-LPS (1 μg/mL ) After treatment, temperature of 37 ℃, 5% CO 2 Cultured for 14 days under culture conditions. After completion of incubation, cells were fixed with 4% formaldehyde for 30 minutes, stained with 0.1% Alizarin Red S (pH 4.3) for 1 hour, washed with deionized water for 30 minutes at room temperature, and then observed as mineralized nodules under a microscope. ) After confirming the formation, it was dissolved in 400 uL of 10% cetylpyridinium chloride and the absorption (570 nm) was measured and shown in Figures 2 and 3.
도 2 및 도 3에서 보는 바와 같이, 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder) 모두 PG-LPS로 인해 조골분화가 억제된 인간 치주인대 세포의 조골분화능을 증가시켰으며, 인간 치주인대세포의 광물화(mineralization)를 효과적으로 유도하였다.As shown in Figures 2 and 3, both steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) increased the osteoblast differentiation ability of human periodontal ligament cells, whose osteoblast differentiation was suppressed by PG-LPS. It effectively induced mineralization of human periodontal ligament cells.
2.2 인간 치주인대세포의 조골분화 특이적 유전자 발현 유도효과 평가2.2 Evaluation of the effect of inducing osteoblastic differentiation-specific gene expression in human periodontal ligament cells
인간 치주인대 (Human preiodontal ligament, HPDL) 세포를 5×105 cell/mL의 농도로 6-well plate에 37 ℃의 온도, 5% CO2
배양조건하에 24시간 배양하였다. 이후, 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)를 0, 50, 100, 150 및 200 μg/mL의 농도로 6시간 처리한 후, PG-LPS (1 μg/mL)로 12시간 자극하였다. 그 후 TRIzol/chloroform reagent를 이용하여 추출된 총 cDNA를 nanodrop으로 정량 후 PrimeScript-RT reagent kit (SYBR Premix Ex Taq)를 이용하여 alp, ocn 및 mmp9의 유전자를 증폭하여 분석하였다. 이 후 각 유전자의 역치(Ct) 값을 GAPDH 수치로 정규화하여 도 2 및 도 3에 나타내었다.Human preiodontal ligament (HPDL) cells were cultured in a 6-well plate at a concentration of 5×10 5 cells/mL at a temperature of 37°C and 5% CO 2 . Cultured for 24 hours under culture conditions. Afterwards, steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) was treated for 6 hours at concentrations of 0, 50, 100, 150, and 200 μg/mL, followed by PG-LPS (1 μg/mL). was stimulated for 12 hours. Afterwards, the total cDNA extracted using TRIzol/chloroform reagent was quantified using nanodrop, and the genes of alp, ocn, and mmp9 were amplified and analyzed using PrimeScript-RT reagent kit (SYBR Premix Ex Taq). Afterwards, the threshold (Ct) value of each gene was normalized to the GAPDH level and shown in Figures 2 and 3.
도 2 및 도 3에서 보는 바와 같이, 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder) 모두 PG-LPS로 인해 손실된 골 활성 지표인 alp, 및 ocn 유전자의 발현을 농도 의존적으로 증가시켰다. 또한, 조골분화가 억제된 인간 치주인대 세포의 조골분화능을 증가시켰으며, 인간 치주인대세포의 광물화(mineralization)를 효과적으로 유도하였다. 또한 잇몸의 결합조직을 파괴하는 MMP9(Matrix metalloproteinase9)효소의 발현을 농도 의존적으로 억제하였다.As shown in Figures 2 and 3, both steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) concentration-dependently expressed the expression of alp and ocn genes, which are indicators of bone activity lost due to PG-LPS. increased. In addition, it increased the osteoblastic differentiation ability of human periodontal ligament cells whose osteoblast differentiation was suppressed and effectively induced mineralization of human periodontal ligament cells. In addition, the expression of MMP9 (Matrix metalloproteinase 9) enzyme, which destroys gum connective tissue, was suppressed in a concentration-dependent manner.
<실험예 3. 증숙 인삼열매 농축물의 항산화 효과 확인><Experimental Example 3. Confirmation of antioxidant effect of steamed ginseng fruit concentrate>
치주염의 원인 또는 진행 과정 중 발생하는 활성산소는 치주조직을 손상시켜 치주질환을 유발하거나 진행 중인 치주질환을 악화시키는 작용을 한다. 유해산소로 알려진 활성산소는 과산화지질을 형성하므로, 이러한 활성산소의 과산화지질이 정상적으로 소거되지 않았을 때, 치주염을 포함한 다양한 염증반응을 일으킨다. 따라서, 항산화 작용을 통한 산화적 스트레스의 생성 억제는 치주염 개선의 중요 작용기전으로 알려져 있다. 이에 따라 PG-LPS로 자극된 인간 치주인대세포에서 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)의 활성산소 (reactive oxygen species, ROS) 제거 및 항산화 효소 (Superoxide Dismutase, SOD), 카탈라제 (Catalase, CAT) 생성 수준에 미치는 영향을 평가하였다.Active oxygen generated during the cause or progression of periodontitis damages periodontal tissue, causing periodontal disease or worsening ongoing periodontal disease. Free radicals, known as harmful oxygen, form lipid peroxides, so when the lipid peroxides of these free radicals are not properly eliminated, they cause various inflammatory reactions, including periodontitis. Therefore, suppressing the production of oxidative stress through antioxidant action is known to be an important mechanism for improving periodontitis. Accordingly, in human periodontal ligament cells stimulated with PG-LPS, steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) removed reactive oxygen species (ROS) and produced antioxidant enzymes (Superoxide Dismutase, SOD). , the effect on the level of catalase (CAT) production was evaluated.
3.1 항산화능 평가3.1 Antioxidant activity evaluation
인간 치주인대 (Human preiodontal ligament, HPDL) 세포를 5×103 cell/mL의 농도로 6-well plate에 37 ℃의 온도, 5% CO2
배양조건하에 24시간 배양하였다. 이후, 0, 50, 100, 150 및 200 μg/mL의 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder) 및 PG-LPS (1 μg/mL)를 처리 후 37 ℃의 온도, 5% CO2
배양조건 하에 2시간 배양하였다. 배양 종료 후 10 μM 디클로로플로레신 디아세테이트(Dichlorofluorescin diacetate, DCF-DA)가 첨가된 배지를 세포에 처리하여 30 min 간 37 ℃의 온도, 5% CO2
배양조건 하에 배양하였고, 배양한 세포는 PBS로 세척하여 1% trypsin-EDTA 용액을 처리한 후 세포를 수확하고, 다시 PBS 로 세척하여 처리하여 30 min 간 배양과 동시에 Incucyte® Live-Cell 분석 시스템을 이용하여 ROS의 변화량을 측정하여 도 4 및 도 5에 나타내었다.Human preiodontal ligament (HPDL) cells were cultured in a 6-well plate at a concentration of 5×10 3 cell/mL at a temperature of 37°C and 5% CO 2 . Cultured for 24 hours under culture conditions. Afterwards, 0, 50, 100, 150, and 200 μg/mL of steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) and PG-LPS (1 μg/mL) were treated at a temperature of 37°C, 5% CO2 Cultured for 2 hours under culture conditions. After completion of incubation, cells were treated with medium supplemented with 10 μM dichlorofluorescin diacetate (DCF-DA) for 30 min at a temperature of 37°C and 5% CO 2. Cultured under culture conditions, the cultured cells were washed with PBS, treated with 1% trypsin-EDTA solution, harvested, washed again with PBS, incubated for 30 min, and incubated with the Incucyte® Live-Cell analysis system. The amount of change in ROS was measured and shown in Figures 4 and 5.
도 4 및 도 5에서 보는 바와 같이, 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder) 모두 PG-LPS로 인해 증가된 활성산소종(ROS) 생성을 농도 의존적으로 감소시켰다. 이들 활성산소는 세포구성 성분인 인지질, 단백질, 당, DNA 등에 대하여 비선택적, 비가역적인 파괴작용을 나타냄으로써 치주염을 일으킨다. 따라서, 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)는 항산화 작용을 통한 산화적 스트레스 억제효과를 측정하여 치주염을 개선시킴을 알 수 있다.As shown in Figures 4 and 5, both steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) reduced the increased production of reactive oxygen species (ROS) due to PG-LPS in a concentration-dependent manner. These active oxygen species cause periodontitis by causing non-selective and irreversible destruction of cellular components such as phospholipids, proteins, sugars, and DNA. Therefore, it can be seen that steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) improves periodontitis by measuring the effect of suppressing oxidative stress through antioxidant action.
3.2 항산화 효소 보호효과 평가3.2 Evaluation of antioxidant enzyme protection effect
초과산화물 불균등화효소(Superoxide dismutase, SOD), 카탈라제(Catalase, CAT) 및 글루타티온 과산화효소(Glutathione Peroxidase, GPx)는 항산화 효능을 촉매하는 효소로 활성산소에 의한 세포 손상에 대응하는 첫 번째 방어 라인을 구성한다. 본 발명에서는 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)가 PG-LPS로 자극된 인간 치주인대세포의 손실된 이들 항산화 효소의 단백질 발현에 영향을 미치는지 확인하였다.Superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) are enzymes that catalyze antioxidant efficacy and form the first line of defense against cell damage caused by free radicals. Compose. In the present invention, it was determined whether steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) affects the protein expression of these antioxidant enzymes in human periodontal ligament cells stimulated with PG-LPS.
인간 치주인대 (Human preiodontal ligament, HPDL) 세포를 5×105 cell/mL의 농도로 6-well plate에 37℃의 온도, 5% CO2
배양조건하에 24시간 배양한 후, 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)를 0, 50, 100, 150 및 200 μg/mL의 농도로 6시간 처리 후 PG-LPS로 12시간 자극하였다. 그 다음 세포 용해 완충액 (RIPA buffer)로 용해 후, 23,000×g에서 15분 동안 원심분리 후, Bradford assay를 실시하여 각 군별 단백질 농도를 정량하고, 정량된 단백질은 SDS/12% 폴리아크릴아미드 겔의 각 웰에 20 μg을 로딩한 후 PVDF 멤브레인으로 옮겼다. 이후, PVDF 멤브레인 스킴밀크 실온에서 1시간 동안 블로킹 후 SOD, CAT 및 GPx의 1차 항체를 4℃에서 24시간 동안 각각 반응시킨 후 순차적으로 각 해당 1차 항체에 대한 2차 항체를 반응시켰다. 각 항체에 결합하여 활성화된 단백질은 ECL 웨스턴 블롯팅 검출 이미징 시스템을 사용하여 측정하고 그 결과를 도 4 및 도 5에 나타내었다.Human periodontal ligament (HPDL) cells were grown in a 6-well plate at a concentration of 5×10 5 cells/mL at a temperature of 37°C and 5% CO 2 . After culturing for 24 hours under culture conditions, treatment with steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) at concentrations of 0, 50, 100, 150, and 200 μg/mL for 6 hours and then treated with PG-LPS. Stimulation was performed for 12 hours. Then, after lysis with cell lysis buffer (RIPA buffer), centrifugation at 23,000 20 μg was loaded into each well and transferred to a PVDF membrane. Afterwards, after blocking with PVDF membrane skim milk at room temperature for 1 hour, the primary antibodies of SOD, CAT, and GPx were each reacted at 4°C for 24 hours, and then the secondary antibodies for each corresponding primary antibody were sequentially reacted. Proteins activated by binding to each antibody were measured using an ECL Western blotting detection imaging system, and the results are shown in Figures 4 and 5.
도 4 및 도 5에서 보는 바와 같이, 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)는 PG-LPS로 자극된 인간 치주인대세포의 손실된 이들 항산화 효소 SOD, CAT 및 GPx의 단백질 발현을 농도 의존적으로 상향 조절하였다. 이러한 연구결과는 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)가 항산화 작용을 통해 산화적 스트레스를 억제효과를 나타낼 수 있음을 확인하였다.As shown in Figures 4 and 5, steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) contains the antioxidant enzymes SOD, CAT and GPx lost from human periodontal ligament cells stimulated with PG-LPS. Protein expression was upregulated in a concentration-dependent manner. These research results confirmed that steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) can suppress oxidative stress through antioxidant activity.
<실험예 4. 증숙 인삼열매 농축물의 항균 효과 확인><Experimental Example 4. Confirmation of antibacterial effect of steamed ginseng fruit concentrate>
치주염을 일으키는 주요한 원인은 구강 내 존재하는 세균으로, 치태 내에 존재하는 수 종의 세균에 의한 혼합감염으로 치주조직의 반응에 따른 염증진행에 의하여 치주질환이 발생된다. 이러한 세균 중 특히 레드 콤플렉스(red complex)에 속하는 포르피로모나스 진지발리스(Porphyromonas gingivalis)는 치주질환의 가장 중요한 원인균으로 알려져 있다. P. gingivalis는 그람 음성 혐기성 세균으로 치주질환자의 병소에서 그 수가 증가되며 치주질환이 진행됨에 따라 열구상피에서도 종종 발견된다. P. gingivalis는 숙주조직과 세포에 부착 또는 침투하는 과정에서 대사산물 또는 독소를 만들어 치주 조직에 직접 해를 미치기도 하지만 P.gingivalis와 반응 하는 세포에서 생산되는 사이토카인(cytokine), 그리고 사이토카인에 반응하는 숙주세포에서 생산된 물질이 치주 조직을 더욱 파괴시킴으로써 치주염을 가속화시킨다. 따라서 치주염을 일으키는 원인 세균 중 대표적인 균인 P. gingivalis에 대한 증숙 인삼열매 농축물의 항균효과를 조사하였다.The main cause of periodontitis is bacteria present in the oral cavity, and periodontal disease occurs due to inflammatory progression due to the reaction of periodontal tissue due to mixed infection caused by several types of bacteria present in plaque. Among these bacteria, Porphyromonas gingivalis, which belongs to the red complex, is known to be the most important cause of periodontal disease. P. gingivalis is a Gram-negative anaerobic bacterium that increases in number in the lesions of patients with periodontal disease, and is often found in the crevicular epithelium as periodontal disease progresses. P. gingivalis produces metabolites or toxins in the process of attaching to or infiltrating host tissues and cells, causing direct harm to periodontal tissue, but is also caused by cytokines produced in cells that react with P. gingivalis , and cytokines. Substances produced by reacting host cells further destroy periodontal tissue, thereby accelerating periodontitis. Therefore, we investigated the antibacterial effect of steamed ginseng fruit concentrate against P. gingivalis, a representative bacteria causing periodontitis.
4.1 증숙 인삼열매 농축물의 최소저해농도 평가4.1 Evaluation of minimum inhibitory concentration of steamed ginseng fruit concentrate
최소저해농도(Minimal Inhibitory Concentration, MIC)는 항균력을 측정하는 가장 기초적인 지표로, 시험관내 세균 감수성 검사(in vitro sensitivity test)에서 미생물의 번식을 억제할 수 있는 최소의 시험물질 농도이다.Minimum Inhibitory Concentration (MIC) is the most basic indicator for measuring antibacterial activity and is the minimum test substance concentration that can inhibit the growth of microorganisms in an in vitro bacterial susceptibility test.
P. gingivalis (KCTC 5352) 균주는 한국생명공학연구원 전북분원 생물자원센터에서 분양 받았다. TSA(Tryptic Soy Agar) 헤민 메나디온 배지(hemin menadione medium)에 1 × 105 [CFU]/mL의 농도로 주입 후 증숙 인삼열매 농축액(EX) 또는 증숙 인삼열매 농축액 파우더(EX powder)를 0, 2.5, 5, 10, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200 및 220 μg/mL의 농도로 처리하고 37 ℃의 온도 혐기성 조건에서 배양하였다. 배양 종료 후 마이크로플레이트 분석기를 이용하여 600 nm 파장으로 흡광을 분석하여 MIC를 분석하고 그 결과를 도 6 및 도 7에 나타내었다. P. gingivalis (KCTC 5352) The strain was distributed from the Biological Resources Center of the Jeonbuk Branch of the Korea Research Institute of Bioscience and Biotechnology. After injecting into TSA (Tryptic Soy Agar) hemin menadione medium at a concentration of 1 × 10 5 [CFU]/mL, steamed ginseng fruit concentrate (EX) or steamed ginseng fruit concentrate powder (EX powder) was added to 0, Treated at concentrations of 2.5, 5, 10, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, and 220 μg/mL and cultured under anaerobic conditions at 37°C. After completion of the culture, the MIC was analyzed by analyzing the absorbance at a wavelength of 600 nm using a microplate analyzer, and the results are shown in Figures 6 and 7.
도 6 및 도 7에서 보는 바와 같이, 증숙 인삼열매 농축액(EX)은 160 μg/mL, 증숙 인삼열매 농축액 파우더(EX powder)는 160 μg/mL부터 P. gingivalis 의 증식이 관찰되지 않아 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder)의 P. gingivalis에 대한 최소억제농도(MIC)는 각각 160 μg/mL 및 180 μg/mL 이었다.As shown in Figures 6 and 7, the growth of P. gingivalis was not observed from 160 μg/mL for steamed ginseng fruit concentrate (EX) and 160 μg/mL for steamed ginseng fruit concentrate powder (EX powder), so that the steamed ginseng fruit The minimum inhibitory concentration (MIC) of concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) against P. gingivalis was 160 μg/mL and 180 μg/mL, respectively.
4.2 증숙 인삼열매 농축물의 최소살균농도 평가4.2 Evaluation of minimum sterilization concentration of steamed ginseng fruit concentrate
최소저해농도(MIC)가 세균의 가시적인 성장을 억제하는데 필요한 항균제의 최저 농도를 의미한다면 최소살균농도(Minimal Bicteriocidal Concentration, MBC)는 세균을 사멸시키는 항균제의 최소 농도이다.If the Minimum Inhibitory Concentration (MIC) refers to the lowest concentration of an antibacterial agent necessary to inhibit the visible growth of bacteria, the Minimum Bicteriocidal Concentration (MBC) is the minimum concentration of an antibacterial agent that kills bacteria.
상기 실시예 4.1에서 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder)의 P. gingivalis에 대한 최소살균농도(MBC)를 확인하기 위하여 160부터 220 μg/mL 처리군 시료를 재배양하고 그 결과를 도 8 및 도 9에 나타내었다. 도 8 및 도 9에서 보는 바와 같이, 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder) 모두에서 180 μg/mL부터 균주가 자라지 않음을 확인하였다. 이에 따라 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder)의 P. gingivalis에 대한 최소살균농도(MBC)는 동일하게 180 μg/mL임을 확인하였다.In Example 4.1, samples from the 160 to 220 μg/mL treatment group were re-cultivated to confirm the minimum bactericidal concentration (MBC) of the steamed ginseng fruit concentrate (EX) and the steamed ginseng fruit concentrate powder (EX powder) against P. gingivalis. And the results are shown in Figures 8 and 9. As shown in Figures 8 and 9, it was confirmed that the strain did not grow from 180 μg/mL in both steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder). Accordingly, it was confirmed that the minimum bactericidal concentration (MBC) of steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) against P. gingivalis was the same at 180 μg/mL.
상기와 같이, 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder)는 치주질환을 일으키는 주요 원인 세균인 P. gingivalis 균주에 대한 항균 및 살균 효과를 나타내는 것으로 확인되었으며, 이러한 증숙 인삼열매 농축액(EX) 및 증숙 인삼열매 농축액 파우더(EX powder)의 항균 및 살균효과는 상기 확인한 항염, 조골세포 분화 유도 및 항산화 효과와 함께 치주염 조절에 중요한 역할을 할 것이라 판단된다.As described above, steamed ginseng fruit concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) were confirmed to exhibit antibacterial and sterilizing effects against P. gingivalis strains, the main causative bacteria causing periodontal disease, and these steamed ginseng fruits It is believed that the antibacterial and sterilizing effects of concentrate (EX) and steamed ginseng fruit concentrate powder (EX powder) will play an important role in controlling periodontitis along with the anti-inflammatory, osteoblast differentiation inducing, and antioxidant effects identified above.
<제제예 1. 정제의 제조><Formulation Example 1. Preparation of tablets>
본 발명 증숙인삼열매 농축물 20g을 각각 락토오스 175.9g, 감자전분 180g 및 콜로이드성 규산 32g과 혼합하였다. 이 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄해서 14 메쉬체를 통과시켰다. 이것을 건조시키고 여기에 감자전분 160g, 활석 50g 및 스테아린산 마그네슘 5g을 첨가해서 얻은 혼합물을 정제로 만들었다. 20 g of the steamed ginseng fruit concentrate of the present invention was mixed with 175.9 g of lactose, 180 g of potato starch, and 32 g of colloidal silicic acid. A 10% gelatin solution was added to this mixture, then pulverized and passed through a 14 mesh sieve. This was dried and 160g of potato starch, 50g of talc, and 5g of magnesium stearate were added to make the resulting mixture into tablets.
<제제예 2. 파우더의 제조><Formulation Example 2. Preparation of powder>
본 발명 증숙인삼열매 농축물 20g에 덱스트린 50g과 혼합한 후 통상의 파우더 제조방법에 따라 상기 성분을 혼합하고 스프레이 드라이하여 파우더를 제조하였다.20 g of the steamed ginseng fruit concentrate of the present invention was mixed with 50 g of dextrin, then the ingredients were mixed and spray dried according to a conventional powder manufacturing method to prepare a powder.
<제제예 3. 캡슐제의 제조><Formulation example 3. Preparation of capsule>
본 발명 증숙인삼열매 농축물 100㎎, 옥수수전분 100㎎, 유당 100㎎ 및 스테아린산 마그네슘 2㎎을 혼합한 후 통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.According to the present invention, 100 mg of steamed ginseng fruit concentrate, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate are mixed, then the above ingredients are mixed according to a typical capsule manufacturing method and filled into a gelatin capsule to prepare a capsule. did.
<제제예 4. 건강기능식품의 제조><Formulation example 4. Manufacturing of health functional food>
본 발명 증숙인삼열매 농축물 20g, 비타민 혼합물 적량, 비타민 A 아세테이트 70㎍, 비타민 E 1.0㎎, 비타민 B1 0.13㎎, 비타민 B2 0.15㎎, 비타민 B6 0.5㎎, 비타민 B12 0.2㎍, 비타민 C 10㎎, 비오틴 10㎍, 니코틴산아미드 1.7㎎, 엽산 50㎍, 판토텐산 칼슘 0.5㎎, 무기질 혼합물 적량, 황산제1철 1.75㎎, 산화아연 0.82㎎, 탄산 마그네슘 25.3㎎, 제1인산칼륨 15㎎, 제2인산칼슘 55㎎, 구연산칼륨 90㎎, 탄산칼슘 100㎎, 염화마그네슘 24.8㎎을 섞어 과립으로 제조하였으나, 용도에 따라 다양한 제형으로 변형시켜 제조할 수 있다. 또한, 상기의 비타민 및 미네랄 혼합물의 조성비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합하여 제조할 수 있다.20g of steamed ginseng fruit concentrate of the present invention, appropriate amount of vitamin mixture, 70㎍ of vitamin A acetate, 1.0㎎ of vitamin E, 0.13㎎ of vitamin B1, 0.15㎎ of vitamin B2, 0.5㎎ of vitamin B6, 0.2㎎ of vitamin B12, 10㎎ of vitamin C, biotin 10㎍, nicotinic acid amide 1.7㎎, folic acid 50㎍, calcium pantothenate 0.5㎎, appropriate amount of mineral mixture, ferrous sulfate 1.75㎎, zinc oxide 0.82㎎, magnesium carbonate 25.3㎎, potassium phosphate monobasic 15㎎, calcium phosphate 255 ㎎, 90㎎ potassium citrate, 100㎎ calcium carbonate, and 24.8㎎ magnesium chloride were mixed to form granules, but it can be manufactured by modifying it into various dosage forms depending on the purpose. In addition, the composition ratio of the above vitamin and mineral mixture may be modified arbitrarily, and the above ingredients may be mixed according to a typical health functional food manufacturing method.
<제제예 5. 건강기능성 음료의 제조><Formulation example 5. Manufacturing of health functional beverage>
본 발명 증숙인삼열매 농축물 1g, 구연산 0.1g, 프락토올리고당 100g, 정제수 900g을 섞어 통상의 음료 제조방법에 따라 교반, 가열, 여과, 살균, 냉장하여 음료를 제조하였다.A beverage was prepared by mixing 1 g of the steamed ginseng fruit concentrate of the present invention, 0.1 g of citric acid, 100 g of fructooligosaccharide, and 900 g of purified water and stirring, heating, filtering, sterilizing, and refrigerating according to a typical beverage production method.
Claims (12)
- 증숙 인삼열매 추출물을 유효성분으로 포함하는 구강질환 예방 또는 치료용 조성물.A composition for preventing or treating oral diseases containing steamed ginseng fruit extract as an active ingredient.
- 제1항에 있어서,According to paragraph 1,상기 증숙 인삼열매 추출물은 인삼열매의 50% 주정 추출물을 100~130℃ 온도, 0.11~15㎫ 압력에서 4~12시간 동안 증숙한 것임을 특징으로 하는 구강질환 예방 또는 치료용 조성물.The steamed ginseng fruit extract is a composition for preventing or treating oral diseases, characterized in that 50% alcohol extract of ginseng fruit is steamed for 4 to 12 hours at a temperature of 100 to 130 ℃ and a pressure of 0.11 to 15 MPa.
- 제1항에 있어서,According to paragraph 1,상기 증숙 인삼열매 추출물은 인삼열매의 50% 주정 추출물을 300~400W, 2.5~3.5㎫ 조건에서 110~130℃로 30~90분 동안 마이크로웨이브를 조사하여 마이크로웨이브 증숙처리한 것임을 특징으로 하는 구강질환 예방 또는 치료용 조성물.Oral disease, characterized in that the steamed ginseng fruit extract is microwave-steamed by irradiating 50% alcohol extract of ginseng fruit with a microwave at 110-130°C for 30-90 minutes under conditions of 300-400 W and 2.5-3.5 MPa. Composition for prevention or treatment.
- 제1항에 있어서,According to paragraph 1,상기 증숙 인삼열매 추출물은 진세노사이드 Rg6 0.5~2중량%, 진세노사이드 Rg4 0.5~2중량%, 및 진세노사이드 Rh4 0.5~5중량%를 포함하는 것을 특징으로 하는 구강질환 예방 또는 치료용 조성물.The steamed ginseng fruit extract is a composition for preventing or treating oral diseases, characterized in that it contains 0.5 to 2% by weight of ginsenoside Rg6, 0.5 to 2% by weight of ginsenoside Rg4, and 0.5 to 5% by weight of ginsenoside Rh4. .
- 제1항 내지 제4항 중 어느 한 항에 있어서,According to any one of claims 1 to 4,상기 구강질환은 치아우식증, 치주염 또는 치은염인 것을 특징으로 하는 구강질환 예방 또는 치료용 조성물.A composition for preventing or treating oral diseases, wherein the oral diseases are dental caries, periodontitis, or gingivitis.
- 제1항 내지 제4항 중 어느 한 항에 있어서,According to any one of claims 1 to 4,상기 조성물은 포르피로모나스 진지발리스(Porphyromonas gingivalis) 균주에 대한 항균 효과가 있는 것을 특징으로 하는 구강질환 예방 또는 치료용 조성물.The composition is a composition for preventing or treating oral diseases, characterized in that it has an antibacterial effect against Porphyromonas gingivalis strains.
- 제1항 내지 제4항 중 어느 한 항에 있어서,According to any one of claims 1 to 4,상기 조성물은 치주인대세포에서 IL-6, IL-1β 또는 TNF-α의 염증성 사이토카인의 발현을 억제하는 것을 특징으로 하는 치주염 예방 또는 치료용 조성물.The composition is a composition for preventing or treating periodontitis, characterized in that it inhibits the expression of inflammatory cytokines IL-6, IL-1β or TNF-α in periodontal ligament cells.
- 제1항 내지 제4항 중 어느 한 항에 있어서,According to any one of claims 1 to 4,상기 조성물은 치주인대세포에서 조골세포의 분화를 유도하는 것을 특징으로 하는 치주염 예방 또는 치료용 조성물.The composition is a composition for preventing or treating periodontitis, characterized in that it induces differentiation of osteoblasts in periodontal ligament cells.
- 제8항에 있어서,According to clause 8,상기 조골세포의 분화 유도는 알칼라인 포스파타제(alkaline phosphatase, ALP) 또는 오스테오칼신(osteocalcin, OCN)의 발현을 증가시키거나 매트릭스 메탈로프로티나제(Matrix metalloproteinase, MMP)의 발현을 억제하는 것임을 특징으로 하는 치주염 예방 또는 치료용 조성물.Periodontitis, characterized in that the induction of differentiation of osteoblasts involves increasing the expression of alkaline phosphatase (ALP) or osteocalcin (OCN) or suppressing the expression of matrix metalloproteinase (MMP) Composition for prevention or treatment.
- 제1항 내지 제4항 중 어느 한 항에 있어서,According to any one of claims 1 to 4,상기 조성물은 치주인대세포에서 초과산화물 불균등화효소(Superoxide dismutase, SOD), 카탈라제(Catalase, CAT) 또는 글루타티온 과산화효소(Glutathione Peroxidase, GPx)의 발현을 증가시키는 것을 특징으로 하는 치주염 예방 또는 치료용 조성물.The composition is a composition for preventing or treating periodontitis, characterized in that it increases the expression of superoxide dismutase (SOD), catalase (CAT), or glutathione peroxidase (GPx) in periodontal ligament cells. .
- 제1항 내지 제4항 중 어느 한 항에 있어서,According to any one of claims 1 to 4,상기 조성물은 치약, 구강세정제, 구강청정제, 껌, 캔디류, 구강스프레이, 구강용 젤, 구강용 연고제, 구강용 바니쉬, 잇몸 마사지 크림 및 구강용 패치로 이루어진 군으로부터 1이상 선택되는 것으로 특징으로 하는 구강질환 예방 또는 치료용 조성물.The composition is an oral application characterized by one or more selected from the group consisting of toothpaste, mouthwash, mouthwash, gum, candy, oral spray, oral gel, oral ointment, oral varnish, gum massage cream, and oral patch. Composition for preventing or treating disease.
- 제1항 내지 제4항 중 어느 한 항의 증숙 인삼열매 추출물을 유효성분으로 포함하는 치주염 예방 또는 치료용 조성물을 포함하는 건강기능식품.A health functional food comprising a composition for preventing or treating periodontitis comprising the steamed ginseng fruit extract of any one of claims 1 to 4 as an active ingredient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220135575A KR20240055367A (en) | 2022-10-20 | 2022-10-20 | Composition for preventing or treating oral disease comprising extract of steamed ginseng berry |
KR10-2022-0135575 | 2022-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024085659A1 true WO2024085659A1 (en) | 2024-04-25 |
Family
ID=90738256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2023/016183 WO2024085659A1 (en) | 2022-10-20 | 2023-10-18 | Composition for preventing or treating oral disease, containing steamed ginseng berry extract as active ingredient |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20240055367A (en) |
WO (1) | WO2024085659A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150019337A (en) * | 2013-08-13 | 2015-02-25 | 주식회사 한국인삼공사 | Pharmaceutical compositions for anti-inflammation or anti-oxidation containing ginsenoside rh4-enriched extraction |
KR101625474B1 (en) * | 2014-12-05 | 2016-05-31 | 충남대학교산학협력단 | Manufacturing method for mass-production of ginsenoside Rh4 |
KR20200036830A (en) * | 2020-03-26 | 2020-04-07 | 한국과학기술연구원 | Method of producing extract having enhanced contents of gensenoside Rg6, Rk3 and Rh4 from Panax ginseng leaf and use of the extract |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101394832B1 (en) | 2007-06-25 | 2014-05-14 | (주)아모레퍼시픽 | Compositions with antibacterial effect on oral bacteria containing extracts of ginseng fruits |
KR100963465B1 (en) | 2008-02-13 | 2010-06-17 | 주식회사 한국인삼공사 | Composition for Treating of Gingival Disorders Comprising Saponin as an Active Ingredient |
KR20160065472A (en) | 2014-12-01 | 2016-06-09 | 김하준 | Equipped with a secondary bus access scaffolding stairs |
-
2022
- 2022-10-20 KR KR1020220135575A patent/KR20240055367A/en unknown
-
2023
- 2023-10-18 WO PCT/KR2023/016183 patent/WO2024085659A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150019337A (en) * | 2013-08-13 | 2015-02-25 | 주식회사 한국인삼공사 | Pharmaceutical compositions for anti-inflammation or anti-oxidation containing ginsenoside rh4-enriched extraction |
KR101625474B1 (en) * | 2014-12-05 | 2016-05-31 | 충남대학교산학협력단 | Manufacturing method for mass-production of ginsenoside Rh4 |
KR20200036830A (en) * | 2020-03-26 | 2020-04-07 | 한국과학기술연구원 | Method of producing extract having enhanced contents of gensenoside Rg6, Rk3 and Rh4 from Panax ginseng leaf and use of the extract |
Non-Patent Citations (3)
Title |
---|
15 April 2017 (2017-04-15), XUE, PENG;YAO, YANG;YANG, XIU-SHI;FENG, JIA;REN, GUI-XING;: "Improved antimicrobial effect of ginseng extract by heat transformation", XP053036282 * |
15 July 2013 (2013-07-15), KIM, SHIN-JUNG;KIM, JU-DUCK;KO, SUNG-KWON;: "Changes in ginsenoside composition of ginseng berry extracts after a microwave and vinegar process", XP053028972 * |
EUN-NAM KIM, TAE-YOUNG KIM, EUI KYUN PARK, JAE-YOUNG KIM, GIL-SAENG JEONG: "Panax ginseng Fruit Has Anti-Inflammatory Effect and Induces Osteogenic Differentiation by Regulating Nrf2/HO-1 Signaling Pathway in In Vitro and In Vivo Models of Periodontitis", ANTIOXIDANTS, MDPI AG, vol. 9, no. 12, pages 1221, XP093162190, ISSN: 2076-3921, DOI: 10.3390/antiox9121221 * |
Also Published As
Publication number | Publication date |
---|---|
KR20240055367A (en) | 2024-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018062605A1 (en) | Toothpaste composition containing galenical extract | |
KR101704589B1 (en) | Composition comprising extracts of Magnolia flower and Magnolia officinlis for preventing or treating periodentitis as an active ingredient | |
WO2024106639A1 (en) | Complex hair loss prevention formulation having core-shell structure, and health functional food | |
WO2022010035A1 (en) | Pharmaceutical composition for anticancer comprising herbal extract | |
WO2016186349A2 (en) | Composition, containing quisaqualis indica extract, for preventing or treating prostatic hyperplasia | |
CN113332342A (en) | Traditional Chinese medicine extract for resisting oral helicobacter pylori, oral care product and preparation method thereof | |
WO2016018055A1 (en) | Composition for treating periodontal diseases containing extract of hizikia fusiforme | |
WO2024085659A1 (en) | Composition for preventing or treating oral disease, containing steamed ginseng berry extract as active ingredient | |
WO2009134036A2 (en) | A mushroom mycelium fermentate using acanthopanax bark as substrate, useful in the prevention and treatment of gastritis, and a pharmaceutical using the extract of said fermentate | |
WO2020116862A1 (en) | Lonicera japonica flower water extract-containing pharmaceutical composition for preventing or treating helicobacter pylori infection | |
WO2022203251A1 (en) | Complex composition for preventing or treating hearing loss containing sarpogrelate and vaccinium myrtillus extract as active ingredients | |
KR102430797B1 (en) | pharmaceutical composition for preventing or treating xerostomia | |
KR20110120732A (en) | Composition for treating and preventing periodontal disease and caries comprising bee venom | |
WO2020111540A1 (en) | Pharmaceutical composition for preventing or treating aging or aging-related diseases comprising anthocyanin-polysaccharide complex as active ingredient | |
CN114796034A (en) | Toothpaste and preparation method thereof | |
KR101280868B1 (en) | Pharmaceutical and food composition for preventing or treating cavity and periodontal disease comprising extract of Yacon as effective component | |
WO2023210880A1 (en) | Composition comprising ginsenoside compound k or complex ginsenoside composition for preventing or treating periodontal disease | |
KR20000012854A (en) | Composition for protection and for remedy of periodontal disease having derivatives of triclosan and of ursodesoxycholic acid, and ulmus extract | |
KR20240126809A (en) | Composition for alveolar bone formation and preventing or treating periodontitis comprising extract of Glehnia littoralis | |
Yang et al. | Sanhuang decoction inhibits autophagy of periodontal ligament fibroblasts during orthodontic tooth movement by activating PI3K-Akt-mTOR pathway | |
CN113546137B (en) | A pharmaceutical composition for treating or preventing oral diseases | |
TWI820946B (en) | Oral pharmaceutical composition with anti-periodontal bacteria adhesion function | |
WO2016080666A2 (en) | Composition for preventing or treating dental caries and periodontal disease, containing extract of ambrosia trifida l. or fraction thereof as active ingredient | |
WO2024063543A1 (en) | Composition for preventing or treating cancer using combination therapy, comprising lactobacillus plantarum strain and herbal medicine | |
WO2021020857A1 (en) | Use of composition for prevention, alleviation or treatment of bone loss disorders, containing extracts of reynoutria japonica and cassiae cortex interior |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23880236 Country of ref document: EP Kind code of ref document: A1 |